493 results on '"Bucher HC"'
Number of results to display per page
Search Results
2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries.
- Author
-
Lodi, S, Del Amo, J, Moreno, S, Bucher, HC, Furrer, H, Logan, R, Sterne, J, Pérez-Hoyos, S, Jarrín, I, Phillips, A, Olson, A, Van Sighem, A, Reiss, P, Sabin, C, Jose, S, Justice, A, Goulet, J, Miró, JM, Ferrer, E, Meyer, L, Seng, R, Vourli, G, Antoniadou, A, Dabis, F, Vandenhede, MA, Costagliola, D, Abgrall, S, Hernán, MA, Hernan, M, Bansi, L, Hill, T, Dunn, D, Porter, K, Glabay, A, Orkin, C, Thomas, R, Jones, K, Fisher, M, Perry, N, Pullin, A, Churchill, D, Gazzard, B, Nelson, M, Asboe, D, Bulbeck, S, Mandalia, S, Clarke, J, Delpech, V, Anderson, J, Munshi, S, Post, F, Easterbrook, P, Khan, Y, Patel, P, Karim, F, Duffell, S, Gilson, R, Man, SL, Williams, I, Gompels, M, Dooley, D, Schwenk, A, Ainsworth, J, Johnson, M, Youle, M, Lampe, F, Smith, C, Grabowska, H, Chaloner, C, Ismajani Puradiredja, D, Walsh, J, Weber, J, Kemble, C, Mackie, N, Winston, A, Leen, C, Wilson, A, Bezemer, DO, Gras, LAJ, Kesselring, AM, Van Sighem, AI, Zaheri, S, Van Twillert, G, Kortmann, W, Branger, J, Prins, JM, Kuijpers, TW, Scherpbier, HJ, Van Der Meer, JTM, Wit, FWMN, Godfried, MH, Van Der Poll, T, Nellen, FJB, and Lange, JMA
- Subjects
Humans ,AIDS-Related Opportunistic Infections ,HIV Infections ,Neoplasms ,Anti-Retroviral Agents ,Antiretroviral Therapy ,Highly Active ,Incidence ,Developed Countries ,Adolescent ,Adult ,Aged ,Middle Aged ,United States ,Europe ,Female ,Male ,Young Adult ,HIV ,immune reconstitution inflammatory syndrome ,incidence ,inverse probability weighting ,unmasking ,Antiretroviral Therapy ,Highly Active ,HIV/AIDS ,Infectious Diseases ,Genetics ,Behavioral and Social Science ,Infection ,Rare Diseases ,Lymphoma ,Cancer ,Hematology ,Tuberculosis ,Virology ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences - Abstract
BackgroundThere is little information on the incidence of AIDS-defining events which have been reported in the literature to be associated with immune reconstitution inflammatory syndrome (IRIS) after combined antiretroviral therapy (cART) initiation. These events include tuberculosis, mycobacterium avium complex (MAC), cytomegalovirus (CMV) retinitis, progressive multifocal leukoencephalopathy (PML), herpes simplex virus (HSV), Kaposi sarcoma, non-Hodgkin lymphoma (NHL), cryptococcosis and candidiasis.MethodsWe identified individuals in the HIV-CAUSAL Collaboration, which includes data from six European countries and the US, who were HIV-positive between 1996 and 2013, antiretroviral therapy naive, aged at least 18 years, had CD4 cell count and HIV-RNA measurements and had been AIDS-free for at least 1 month between those measurements and the start of follow-up. For each AIDS-defining event, we estimated the hazard ratio for no cART versus less than 3 and at least 3 months since cART initiation, adjusting for time-varying CD4 cell count and HIV-RNA via inverse probability weighting.ResultsOut of 96 562 eligible individuals (78% men) with median (interquantile range) follow-up of 31 [13,65] months, 55 144 initiated cART. The number of cases varied between 898 for tuberculosis and 113 for PML. Compared with non-cART initiation, the hazard ratio (95% confidence intervals) up to 3 months after cART initiation were 1.21 (0.90-1.63) for tuberculosis, 2.61 (1.05-6.49) for MAC, 1.17 (0.34-4.08) for CMV retinitis, 1.18 (0.62-2.26) for PML, 1.21 (0.83-1.75) for HSV, 1.18 (0.87-1.58) for Kaposi sarcoma, 1.56 (0.82-2.95) for NHL, 1.11 (0.56-2.18) for cryptococcosis and 0.77 (0.40-1.49) for candidiasis.ConclusionWith the potential exception of mycobacterial infections, unmasking IRIS does not appear to be a common complication of cART initiation in high-income countries.
- Published
- 2014
3. Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study
- Author
-
Bayard, Cornelia, Ledergerber, Bruno, Flepp, Markus, Lecompte, Thanh, Moulin, Estelle, Hoffmann, Matthias, Weber, Rainer, Staehelin, Cornelia, Di Benedetto, Caroline, Fux, Christoph A, Tarr, Philip E, Hasse, Barbara, Aubert, V, Battegay, M, Bernasconi, E, Böni, J, Braun, DL, Bucher, HC, Calmy, A, Cavassini, M, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, Fux, CA, Günthard, HF, Haerry, D, Hasse, B, Hirsch, HH, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, RD, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Marzolini, C, Metzner, KJ, Müller, N, Nicca, D, Pantaleo, G, Paioni, P, Rauch, A, Rudin, C, Scherrer, AU, Schmid, P, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Vernazza, P, Wandeler, G, Weber, R, and Yerly, S
- Published
- 2017
- Full Text
- View/download PDF
4. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV‐1 positive patients with well‐estimated dates of seroconversion
- Author
-
Stirrup, OT, Copas, AJ, Phillips, AN, Gill, MJ, Geskus, RB, Touloumi, G, Young, J, Bucher, HC, Babiker, AG, Kelleher, Tony, Cooper, David, Grey, Pat, Finlayson, Robert, Bloch, Mark, Kelleher, Tony, Ramacciotti, Tim, Gelgor, Linda, Smith, Don, Zangerle, Robert, Gill, John, Lutsar, Irja, Chêne, Geneviève, Dabis, Francois, Thiebaut, Rodolphe, Costagliola, Dominique, Guiguet, Marguerite, Vanhems, Philippe, Chaix, Marie‐Laure, Ghosn, Jade, Meyer, Laurence, Boufassa, Faroudy, Hamouda, Osamah, Meixenberger, Karolin, Bannert, Norbert, Bartmeyer, Barbara, Antoniadou, Anastasia, Chrysos, Georgios, Daikos, Georgios L., Pantazis, Nikos, Katsarou, Olga, Rezza, Giovanni, Dorrucci, Maria, Monforte, Antonella, Luca, Andrea, Prins, Maria, Geskus, Ronald, Helm, Jannie, Schuitemaker, Hanneke, Sannes, Mette, Brubakk, Oddbjorn, Kran, Anne‐Marte, Rosinska, Magdalena, Muga, Roberto, Tor, Jordi, Olalla, Patricia, Cayla, Joan, Amo, Julia, Moreno, Santiago, Monge, Susana, Amo, Julia, Romero, Jorge, Pérez‐Hoyos, Santiago, Sönnerborg, Anders, Bucher, C, Günthard, Huldrych, Scherrer, Alexandra, Malyuta, Ruslan, Murphy, Gary, Porter, Kholoud, Johnson, Anne, Babiker, Abdel, Pillay, Deenan, Morrison, Charles, Salata, Robert, Mugerwa, Roy, Chipato, Tsungai, Price, Matt A., Gilmour, Jill, Kamali, Anatoli, and Karita, Etienne
- Published
- 2018
- Full Text
- View/download PDF
5. Antiretroviral pill count and clinical outcomes in treatment‐naïve patients with HIV infection
- Author
-
Young, J, Smith, C, Teira, R, Reiss, P, Jarrín Vera, I, Crane, H, Miro, JM, DʼArminio Monforte, A, Saag, M, Zangerle, R, Bucher, HC, Boulle, Andrew, Stephan, Christoph, Cavassini, Matthias, del Amo, Julia, Fätkenheuer, Gerd, Gill, John, Guest, Jodie, Hans‐Ulrich Haerry, David, Hogg, Robert, Justice, Amy, Shepherd, Leah, Obel, Neils, Sterling, Tim, and Williams, Matthew
- Published
- 2018
- Full Text
- View/download PDF
6. Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017
- Author
-
Ruffieux, Yann, Lemsalu, Liis, Aebi?Popp, Karoline, Calmy, Alexandra, Cavassini, Matthias, Fux, Christoph A., Günthard, Huldrych F., Marzolini, Catia, Scherrer, Alexandra, Vernazza, Pietro, Keiser, Olivia, Egger, Matthias, Anagnostopoulos, A., Battegay, M., Bernasconi, E., Böni, J., Braun, Dl., Bucher, Hc., Ciuffi, A., Dollenmaier, G., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Haerry, D., Hasse, B., Hirsch, Hh., Hoffmann, M., Hösli, I., Huber, M., Kahlert, Cr., Kaiser, L., Klimkait, T., Kouyos, Rd., Kovari, H., Ledergerber, B., Martinetti, G., De Tejada, B. Martinez, Metzner, Kj., Müller, N., Nicca, D., Paioni, P., Pantaleo, G., Perreau, M., Rauch, A., Rudin, C., Schmid, P., Speck, R., Stöckle, M., Tarr, P., Trkola, A., Wandeler, G., Weber, R., and Yerly, S. Tbd.
- Subjects
HIV patients -- Psychological aspects ,Suicide -- Risk factors -- Statistics ,Health - Abstract
: Introduction: In many countries, mortality due to suicide is higher among people living with HIV than in the general population. We aimed to analyse trends in suicide mortality before and after the introduction of triple combination antiretroviral therapy (cART), and to identify risk factors associated with death from suicide in Switzerland. Methods: We analysed data from the Swiss HIV Cohort Study from the pre‐cART (1988‐1995), earlier cART (1996‐2008) and later cART (2009‐2017) eras. We used multivariable Cox regression to assess risk factors for death due to suicide in the ART era and computed standardized mortality ratios (SMRs) to compare mortality rates due to suicide among persons living with HIV with the general population living in Switzerland, using data from the Swiss National Cohort. Results and Discussion: We included 20,136 persons living with HIV, of whom 204 (1.0%) died by suicide. In men, SMRs for suicide declined from 12.9 (95% CI 10.4‐16.0) in the pre‐cART era to 2.4 (95% CI 1.2‐5.1) in the earlier cART and 3.1 (95% CI 2.3‐4.3) in the later cART era. In women, the corresponding ratios declined from 14.2 (95% CI 7.9‐25.7) to 10.2 (3.8‐27.1) and to 3.3 (95% CI 1.5‐7.4). Factors associated with death due to suicide included gender (adjusted hazard ratio 0.58 (95% CI 0.38‐0.87) comparing women with men), nationality (1.95 (95% CI 1.34‐2.83) comparing Swiss with other), Centers for Disease Control and Prevention clinical stage (0.33 (95% CI 0.24‐0.46) comparing stage A with C), transmission group (2.64 (95% CI 1.71‐4.09) for injection drug use and 2.10 (95% CI 1.36‐3.24) for sex between men compared to other), and mental health (2.32 (95% CI 1.71‐3.14) for a history of psychiatric treatment vs. no history). There was no association with age. Conclusions: Suicide rates have decreased substantially among people living with HIV in the last three decades but have remained about three times higher than in the general population since the introduction of cART. Continued emphasis on suicide prevention among men and women living with HIV is important., Introduction Depression, anxiety and other mental health problems are common among people living with HIV, and more common than in the general population or among comparable HIV‐negative people. In the [...]
- Published
- 2019
- Full Text
- View/download PDF
7. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals
- Author
-
Barceló, Catalina, Gaspar, Frédéric, Aouri, Manel, Panchaud, Alice, Rotger, Margalida, Guidi, Monia, Cavassini, Matthias, Buclin, Thierry, Decosterd, Laurent A., Csajka, Chantal, Aubert, V., Battegay, M., Bernasconi, E., Böni, J., Braun, DL, Bucher, HC, Burton-Jeangros, C., Calmy, A., Cavassini, M., Dollenmaier, G., Egger, M., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Fux, CA, Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH, Hoffmann, M., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Klimkait, T., Kouyos, R., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Marzolini, C., Metzner, K., Müller, N., Nadal, D., Nicca, D., Pantaleo, G., Rauch, A., Regenass, S., Rudin, C., Schöni-Affolter, F., Schmid, P., Speck, R., Stöckle, M., Tarr, P., Trkola, A., Vernazza, P., Weber, R., and Yerly, S.
- Subjects
virus diseases - Abstract
Objectives Co-formulated elvitegravir, cobicistat, tenofovir disoproxil fumarate and emtricitabine is among the preferred regimens for first-line ART. A population approach was used to characterize the pharmacokinetics of elvitegravir and cobicistat and identify individual factors and co-medications influencing their disposition, taking into consideration the interaction between the two compounds. Methods The study population included 144 HIV-infected individuals who provided 186 and 167 elvitegravir and cobicistat plasma concentrations, respectively. First, distinct NONMEM® analyses were conducted for elvitegravir and cobicistat, including individual demographic, clinical and genetic factors as potential covariates. Elvitegravir and cobicistat interaction was then assessed through different inhibitory models. Simulations based on the final model served to compare expected drug concentrations under standard and alternative dosage regimens. Results Clearance with between-subject variability was 7.6 L/h [coefficient of variation (CV) 16.6%] and volume of distribution 61 L for elvitegravir and 16.0 L/h (CV 41.9%) and 88.3 L, respectively, for cobicistat. Concomitant administration of non-ritonavir-boosted atazanavir decreased elvitegravir clearance by 35%, likely due to UDP-glucuronosyl transferase (UGT) 1A1 inhibition. Concomitant administration of non-ritonavir-boosted atazanavir and ritonavir-boosted darunavir decreased cobicistat clearance by 47% and 27%, respectively. The final interaction model included cobicistat exposure (AUC0-24) on elvitegravir clearance. Simulations confirmed that a reduced elvitegravir dose of 85 mg co-administered with cobicistat and atazanavir produces a concentration-time course comparable to the standard regimen without atazanavir. Conclusions Elvitegravir and cobicistat pharmacokinetic variability appears to be mainly explained by drug-drug interactions that may be encountered in routine clinical practice. In these cases, therapeutic drug monitoring and surveillance for potential toxicities would be justified.
- Published
- 2021
8. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study
- Author
-
Hatleberg, Camilla I., Ryom, Lene, El?Sadr, Wafaa, Mocroft, Amanda, Reiss, Peter, De Wit, Stephane, Dabis, Francois, Pradier, Christian, Monforte, Antonella D'Arminio, Kovari, Helen, Law, Matthew, Lundgren, Jens D., Sabin, Caroline A., Calvo, G, Bonnet, F, Kirk, O, Morfeldt, L, Weber, R, Lind?Thomsen, A, Brandt, R Salbøl, Hillebreght, M, Zaheri, S, Wit, Fwnm, Scherrer, A, Schöni?Affolter, F, Rickenbach, M, Tavelli, A, Fanti, I, Leleux, O, Mourali, J, Le Marec, F, Boerg, E, Thulin, E, Sundström, A, Bartsch, G, Thompsen, G, Necsoi, C, Delforge, M, Fontas, E, Caissotti, C, Mateu, S, Torres, F, Petoumenos, K, Blance, A, Huang, R, Puhr, R, Laut, K, Kristensen, D, Phillips, An, Kamara, Da, Smith, Cj, Brandt, Rs, Raben, D, Matthews, C, Bojesen, A, Grevsen, Al, Powderly, B, Shortman, N, Moecklinghoff, C, Reilly, G, Franquet, X, Smit, C, Ross, M, Fux, Ca, Morlat, P, Friis?Møller, N, Kowalska, J, Bohlius, J, Bower, M, Fätkenheuer, G, Grulich, A, Sjøl, A, Meidahl, P, Iversen, Js, Hillebregt, M, Prins, Jm, Kuijpers, Tw, Scherpbier, Hj, Meer, Jtm, Godfried, Mh, Poll, T, Nellen, Fjb, Geerlings, Se, Vugt, M, Pajkrt, D, Bos, Jc, Wiersinga, Wj, Valk, M, Goorhuis, A, Hovius, Jw, Eden, J, Henderiks, A, Hes, Amh, Mutschelknauss, M, Nobel, He, Pijnappel, Fjj, Jurriaans, S, Back, Nkt, Zaaijer, Hl, Berkhout, B, Cornelissen, Mte, Schinkel, Cj, Thomas, Xv, Ziekenhuis, A De Ruyter, Berge, M, Stegeman, A, Baas, S, De Looff, L Hage, Ziekenhuis, C, Pronk, Mjh, Ammerlaan, Hsm, Munnik, E, Tjhie, J, Wegdam, Mca, Deiman, B, Scharnhorst, V, Weijsenfeld, Am, Ende, Me, Gorp, Ecm, Schurink, Cam, Nouwen, Jl, Verbon, A, Rijnders, Bja, Bax, Hi, Feltz, M, Bassant, N, Beek, Jea, Vriesde, M, Zonneveld, Lm, Oude?Lubbers, A, Berg?Cameron, Hj, Bruinsma?Broekman, Fb, Groot, J, Man, M Zeeuw?De, Boucher, Cab, Koopmans, Mpg, Kampen, Jja, Pas, Sd, Driessen, Gja, Rossum, Amc, Knaap, Lc, Flevoziekenhuis, E, Branger, J, Rijkeboer?Mes, A, Schippers, Ef, Ijperen, Jm, Geilings, J, Hut, G, Franck, Pfh, Eeden, A, Brokking, W, Groot, M, Elsenburg, Ljm, Damen, M, Isala, Is, Groeneveld, Php, Bouwhuis, Jw, Berg, Jf, Hulzen, Agw, Bliek, Gl, Bor, Pcj, Bloembergen, P, Wolfhagen, Mjhm, Ruijs, Gjhm, Kroon, Fp, Boer, Mgj, Bauer, Mp, Jolink, H, Vollaard, Am, Dorama, W, Holten, N, Claas, Ecj, Wessels, E, Den Hollander, Jg, Pogany, K, Roukens, A, Kastelijns, M, Smit, Jv, Smit, E, Struik?Kalkman, D, Tearno, C, Bezemer, M, Niekerk, T, Pontesilli, O, Lowe, Sh, Lashof, Aml Oude, Posthouwer, D, Ackens, Rp, Schippers, J, Vergoossen, R, Weijenberg?Maes, B, Loo, Ihm, Havenith, Tra, Leyten, Ems, Gelinck, Lbs, Hartingsveld, A, Meerkerk, C, Wildenbeest, Gs, Mutsaers, Jaem, Jansen, Cl, Mulder, Jw, Vrouenraets, Sme, Lauw, Fn, Broekhuizen, Mc, Paap, H, Vlasblom, Dj, Smits, Phm, Weijer, S, Moussaoui, R El, Bosma, As, Vonderen, Mga, Houte, Dpf, Kampschreur, Lm, Dijkstra, K, Faber, S, Weel, J, Kootstra, Gj, Delsing, Ce, De Plas, M Burg?Van, Heins, H, Lucas, E, Kortmann, W, Twillert¤, G, Stuart, Jwt Cohen, Diederen, Bmw, Pronk, D, Truijen?Oud, Fa, Reijden, Wa, Jansen, R, Brinkman¤, K, Berk, Gel, Blok, Wl, Frissen, Phj, Lettinga, Kd, Schouten, Wem, Veenstra, J, Brouwer, Cj, Geerders, Gf, Hoeksema, K, Kleene, Mj, Meché, Ib, Spelbrink, M, Sulman, H, Toonen, Ajm, Wijnands, S, Kwa, D, Witte, E, Koopmans, Pp, Keuter, M, Ven, Ajam, Hofstede, Hjm, Dofferhoff, Asm, Crevel, R, Albers, M, Bosch, Mew, Grintjes?Huisman, Kjt, Zomer, Bj, Stelma, Ff, Rahamat?Langendoen, J, Burger, D, Richter, C, Gisolf, Eh, Hassing, Rj, Beest, G, Van Bentum, Phm, Langebeek, N, Tiemessen, R, Swanink, Cma, Lelyveld, Sfl, Soetekouw, R, Hulshoff, N, Prijt, Lmm, Swaluw, J, Bermon, N, Herpers, Bl, Veenendaal, D, Verhagen, Dwm, Wijk, M, Brouwer, Ae, Kuipers, M, Santegoets, Rmwj, Ven, B, Marcelis, Jh, Buiting, Agm, Kabel, Pj, Bierman, Wfw, Scholvinck, H, Wilting, Kr, Stienstra, Y, Meulen, Pa, Weerd, Da, Ludwig?Roukema, J, Niesters, Hgm, Riezebos?Brilman, A, Leer?Buter, Cc, Knoester, M, Hoepelman, Aim, Mudrikova, T, Ellerbroek, Pm, Oosterheert, Jj, Arends, Je, Barth, Re, Wassenberg, Mwm, Schadd, Em, Elst?Laurijssen, Dhm, Oers?Hazelzet, Eeb, Vervoort, S, Berkel, M, Schuurman, R, Verduyn?Lunel, F, Wensing, Amj, Peters, Ejg, Agtmael, Ma, Bomers, M, Vocht, J, Heitmuller, M, Laan, Lm, Pettersson, Am, Ang, Cw, Geelen, Spm, Wolfs, Tfw, Bont, Lj, Bezemer, Do, Sighem, Ai, Boender, Ts, Jong, A, Bergsma, D, Hoekstra, P, Lang, A, Grivell, S, Jansen, A, Rademaker, Mj, Raethke, M, Meijering, R, Schnörr, S, Groot, L, Akker, M, Bakker, Y, Claessen, E, Berkaoui, A El, Koops, J, Kruijne, E, Lodewijk, C, Munjishvili, L, Peeck, B, Ree, C, Regtop, R, Ruijs, Y, Rutkens, T, Sande, L, Schoorl, M, Timmerman, A, Tuijn, E, Veenenberg, L, Vliet, S, Wisse, A, Woudstra, T, Tuk, B, Dupon, M, Gaborieau, V, Lacoste, D, Malvy, D, Mercié, P, Neau, D, Pellegrin, Jl, Tchamgoué, S, Lazaro, E, Cazanave, C, Vandenhende, M, Vareil, Mo, Gérard, Y, Blanco, P, Bouchet, S, Breilh, D, Fleury, H, Pellegrin, I, Chêne, G, Thiébaut, R, Wittkop, L, Lawson?Ayayi, S, Gimbert, A, Desjardin, S, Lacaze?Buzy, L, Petrov?Sanchez, V, André, K, Bernard, N, Caubet, O, Caunegre, L, Chossat, I, Courtault, C, Dauchy, Fa, Dondia, D, Duffau, P, Dutronc, H, Farbos, S, Faure, I, Ferrand, H, Gerard, Y, Greib, C, Hessamfar, M, Imbert, Y, Lataste, P, Marie, J, Mechain, M, Monlun, E, Ochoa, A, Pistone, T, Raymond, I, Receveur, Mc, Rispal, P, Sorin, L, Valette, C, Vandenhende, Ma, Viallard, Jf, Wille, H, Wirth, G, Lafon, Me, Trimoulet, P, Bellecave, P, Tumiotto, C, Haramburu, F, Miremeont?Salamé, G, Blaizeau, Mj, Decoin, M, Hannapier, C, Pougetoux, E Lenaud Et A., Delveaux, S, D' Ivernois, C, Diarra, F, Uwamaliya?Nziyumvira, B, Palmer, G, Conte, V, Sapparrart, V, Moore, R, Edwards, S, Hoy, J, Watson, K, Roth, N, Lau, H, Bloch, M, Baker, D, Carr, A, Cooper, D, O'Sullivan, M, Nolan, D, Guelfi, G, Domingo, P, Sambeat, Ma, Gatell, J, Del Cacho, E, Cadafalch, J, Fuster, M, Codina, C, Sirera, G, Vaqué, A, Clumeck, N, Gennotte, Af, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Martin, C, Payen, Mc, Semaille, P, Laethem, Y, Neaton, J, Krum, E, Thompson, G, Luskin?Hawk, R, Telzak, E, Abrams, Di, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, Lr, Sampson, J, Baxter, J, Gazzard, B, Horban, A, Karpov, I, Losso, M, Pedersen, C, Ristola, M, Phillips, A, Rockstroh, J, Peters, L, Fischer, Ah, Laut, K Grønborg, Larsen, Jf, Podlekareva, D, Cozzi?Lepri, A, Shepherd, L, Schultze, A, Amele, S, Kundro, M, Schmied, B, Vassilenko, A, Mitsura, Vm, Paduto, D, Florence, E, Vandekerckhove, L, Hadziosmanovic, V, Begovac, J, Machala, L, Jilich, D, Kronborg, G, Benfield, T, Gerstoft, J, Katzenstein, T, Møller, Nf, Ostergaard, L, Wiese, L, Nielsen, Ln, Zilmer, K, Aho, I, Viard, J?P, Girard, P?M, Duvivier, C, Degen, O, Stellbrink, Hj, Stefan, C, Bogner, J, Chkhartishvili, N, Gargalianos, P, Szlávik, J, Gottfredsson, M, Mulcahy, F, Yust, I, Turner, D, Burke, M, Shahar, E, Hassoun, G, Elinav, H, Haouzi, M, Elbirt, D, Sthoeger, Zm, Esposito, R, Mazeu, I, Mussini, C, Mazzotta, F, Gabbuti, A, Vullo, V, Lichtner, M, Zaccarelli, M, Antinori, A, Acinapura, R, Plazzi, M, Lazzarin, A, Castagna, A, Gianotti, N, Galli, M, Ridolfo, A, Rozentale, B, Uzdaviniene, V, Staub, T, Ormaasen, V, Maeland, A, Bruun, J, Knysz, B, Gasiorowski, J, Inglot, M, Bakowska, E, Flisiak, R, Grzeszczuk, A, Parczewski, M, Maciejewska, K, Aksak?Was, B, Beniowski, M, Mularska, E, Smiatacz, T, Gensing, M, Jablonowska, E, Malolepsza, E, Wojcik, K, Mozer?Lisewska, I, Caldeira, L, Radoi, R, Panteleev, A, Yakovlev, A, Trofimora, T, Khromova, I, Kuzovatova, E, Borodulina, E, Vdoushkina, E, Jevtovic, D, Tomazic, J, Gatell, Jm, Miró, Jm, Moreno, S, Rodriguez, Jm, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gutierrez, M, Mateo, G, Laporte, Jm, Falconer, K, Thalme, A, Sonnerborg, A, Blaxhult, A, Flamholc, L, Cavassini, M, Calmy, A, Furrer, H, Schmid, P, Kuznetsova, A, Kyselyova, G, Sluzhynska, M, Johnson, Am, Simons, E, Johnson, Ma, Orkin, C, Weber, J, Scullard, G, Clarke, A, Leen, C, Thulin, G, Åkerlund, B, Koppel, K, Karlsson, A, Håkangård, C, Castelli, F, Cauda, R, Di Perri, G, Iardino, R, Ippolito, G, Marchetti, Gc, Perno, Cf, Schloesser, F, Viale, P, Ceccherini?Silberstein, F, Girardi, E, Lo Caputo, S, Puoti, M, Andreoni, M, Ammassari, A, Balotta, C, Bandera, A, Bonfanti, P, Bonora, S, Borderi, M, Calcagno, A, Calza, L, Capobianchi, Mr, Cingolani, A, Cinque, P, De Luca, A, Di Biagio, A, Gori, A, Guaraldi, G, Lapadula, G, Madeddu, G, Maggiolo, F, Marchetti, G, Marcotullio, S, Monno, L, Nozza, S, Roldan, E Quiros, Rossotti, R, Rusconi, S, Santoro, Mm, Saracino, A, Galli, L, Lorenzini, P, Rodano, A, Shanyinde, M, Carletti, F, Carrara, S, Di Caro, A, Graziano, S, Petrone, F, Prota, G, Quartu, S, Truffa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Santoro, C, Suardi, C, Donati, V, Verucchi, G, Minardi, C, Quirino, T, Abeli, C, Manconi, Pe, Piano, P, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Vichi, F, Cassola, G, Viscoli, C, Alessandrini, A, Bobbio, N, Mazzarello, G, Mastroianni, C, Belvisi, V, Caramma, I, Chiodera, A, Milini, P, Rizzardini, G, Moioli, Mc, Piolini, R, Ridolfo, Al, Salpietro, S, Tincati, C, Puzzolante, C, Abrescia, N, Chirianni, A, Borgia, G, Orlando, R, Bonadies, G, Di Martino, F, Gentile, I, Maddaloni, L, Cattelan, Am, Marinello, S, Cascio, A, Colomba, C, Baldelli, F, Schiaroli, E, Parruti, G, Sozio, F, Magnani, G, Ursitti, Ma, Cristaudo, A, Baldin, G, Capozzi, M, Cicalini, S, Sulekova, L Fontanelli, Iaiani, G, Latini, A, Mastrorosa, I, Plazzi, Mm, Savinelli, S, Vergori, A, Cecchetto, M, Viviani, F, Bagella, P, Rossetti, B, Franco, A, Del Vecchio, R Fontana, Francisci, D, Di Giuli, C, Caramello, P, Orofino, Gc, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, Manfrin, V, Starnini, G, Ialungo, A, Dollet, K, Dellamonica, P, Bernard, E, Courjon, J, Cua, E, De Salvador?Guillouet, F, Durant, J, Etienne, C, Ferrando, S, Mondain?Miton, V, Naqvi, A, Perbost, I, Pillet, S, Prouvost?Keller, B, Pugliese, P, Rio, V, Risso, K, Roger, Pm, Aubert, V, Battegay, M, Bernasconi, E, Böni, J, Braun, Dl, Bucher, Hc, Ciuffi, A, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Günthard, Hf, Haerry, D, Hasse, B, Hirsch, Hh, Hoffmann, M, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, Rd, Ledergerber, B, Martinetti, G, De Tejada, B Martinez, Marzolini, C, Metzner, Kj, Müller, N, Nicca, D, Pantaleo, G, Paioni, P, Rauch, A, Rudin, C, Scherrer, Au, Speck, R, Stöckle, M, Tarr, P, Trkola, A, Vernazza, P, Wandeler, G, and Yerly, S
- Subjects
Medical care -- Utilization ,Cardiovascular system -- Surgery ,Sex factors in disease -- Analysis ,HIV patients -- Statistics -- Care and treatment -- Demographic aspects ,Health - Abstract
: Introduction: There is paucity of data related to potential gender differences in the use of interventions to prevent and treat cardiovascular disease (CVD) among HIV‐positive individuals. We investigated whether such differences exist in the observational D:A:D cohort study. Methods: Participants were followed from study enrolment until the earliest of death, six months after last visit or February 1, 2015. Initiation of CVD interventions [lipid‐lowering drugs (LLDs), angiotensin‐converting enzyme inhibitors (ACEIs), anti‐hypertensives, invasive cardiovascular procedures (ICPs) were investigated and Poisson regression models calculated whether rates were lower among women than men, adjusting for potential confounders. Results: Women (n = 12,955) were generally at lower CVD risk than men (n = 36,094). Overall, initiation rates of CVD interventions were lower in women than men; LLDs: incidence rate 1.28 [1.21, 1.35] vs. 2.40 [2.34, 2.46]; ACEIs: 0.88 [0.82, 0.93] vs. 1.43 [1.39, 1.48]; anti‐hypertensives: 1.40 [1.33, 1.47] vs. 1.72 [1.68, 1.77] and ICPs: 0.08 [0.06, 0.10] vs. 0.30 [0.28, 0.32], and this was also true for most CVD interventions when exclusively considering periods of follow‐up for which individuals were at high CVD risk. In fully adjusted models, women were less likely to receive CVD interventions than men (LLDs: relative rate 0.83 [0.78, 0.88]; ACEIs: 0.93 [0.86, 1.01]; ICPs: 0.54 [0.43, 0.68]), except for the receipt of anti‐hypertensives (1.17 [1.10, 1.25]). Conclusion: The use of most CVD interventions was lower among women than men. Interventions are needed to ensure that all HIV‐positive persons, particularly women, are appropriately monitored for CVD and, if required, receive appropriate CVD interventions., Introduction HIV‐positive individuals are known to be at increased risk of cardiovascular disease (CVD) compared to the general population, partly due to an increased prevalence of some CVD risk factors, [...]
- Published
- 2018
- Full Text
- View/download PDF
9. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection
- Author
-
Fitzmaurice, Karen, Hurst, Jacob, Dring, Megan, Rauch, Andri, McLaren, Paul J, Günthard, Huldrych F, Gardiner, Clair, Klenerman, Paul, Courtney, Garry, Crosbie, Orla, Crowe, John, Fanning, Liam, Hegarty, John, Kelleher, Dermot, Lawlor, Emer, Lee, John, McKiernan, Susan, Murray, Frank, Norris, Suzanne, OʼFarrelly, Cliona, Thornton, Leila, Aubert, V, Battegay, M, Bernasconi, E, Böni, J, Bucher, HC, Burton-Jeangros, C, Calmy, A, Cavassini, M, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, Fux, CA, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, HH, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, R, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Metzner, K, Müller, N, Nadal, D, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schöni-Affolter, F, Schmid, P, Schultze, D, Schüpbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, and Yerly, S
- Published
- 2015
- Full Text
- View/download PDF
10. Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS).
- Author
-
Hachfeld, Anna, Atkinson, Andrew, Stute, Petra, Calmy, Alexandra, Tarr, Philip E., Darling, Katharine, Babouee Flury, Baharak, Polli, Christian, Sultan‐Beyer, Leila, Abela, Irene A., Aebi‐Popp, Karoline, Abela, A I, Aebi‐Popp, K, Anagnostopoulos, A, Battegay, M, Bernasconi, E, Braun, DL, Bucher, HC, Calmy, A, and Cavassini, M
- Subjects
HIV-positive persons ,THERAPEUTICS ,HORMONES ,GYNECOLOGIC examination ,MEDICAL care use ,DOCUMENTATION ,DISEASE prevalence ,POSTMENOPAUSE ,DESCRIPTIVE statistics ,MENOPAUSE ,LOGISTIC regression analysis ,PREMATURE menopause ,BONE density ,WOMEN'S health ,LONGITUDINAL method - Abstract
Objectives: We aimed to assess prevalence and age at menopause, identify factors associated with early menopause and explore the provision and utilization of healthcare in women living with HIV in Switzerland. Methods: This was a retrospective Swiss HIV Cohort Study analysis from January 2010 to December 2018. Descriptive statistics to characterise the population and menopause onset. Logistic regression analysis to identify risk factors for early menopause. Results: Of all women in the SHCS, the proportion of postmenopausal women tripled from 11.5% (n = 274) in 2010 to 36.1% (n = 961) in 2018. The median age at menopause was 50 years. Early menopause (< 45 years) occurred in 115 (10.2%) women and premature ovarian insufficiency (POI) (< 40 years) in 23 (2%) women. Early menopause was associated with black ethnicity (52.2% vs. 21.6%, p < 0.001), but not with HIV acquisition mode, CDC stage, viral suppression, CD4 cell count, hepatitis C, smoking or active drug use. While 92% of the postmenopausal women underwent a gynaecological examination during the 36 months before menopause documentation, only 27% received a bone mineral density measurement within 36 months after the last bleed and 11% were on hormone replacement therapy at the time of menopause documentation. Conclusions: The median age of women living with HIV at menopause is around 2 years lower than that reported for HIV‐negative women in Switzerland. HIV care providers need to adapt their services to the requirements of the increasing number of women living with HIV transitioning through menopause. They should be able to recognize menopause‐associated symptoms and improve access to bone mineral density measurement as well as hormone replacement therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study
- Author
-
Young, J, Scherrer, AU, Günthard, HF, Opravil, M, Yerly, S, Böni, J, Rickenbach, M, Fux, CA, Cavassini, M, Bernasconi, E, Vernazza, P, Hirschel, B, Battegay, M, and Bucher, HC
- Published
- 2011
- Full Text
- View/download PDF
12. What do the changing patterns of comorbidity burden in people living with HIV mean for long‐term management? Perspectives from European HIV cohorts
- Author
-
d'Arminio Monforte, A, primary, Bonnet, F, additional, Bucher, HC, additional, Pourcher, V, additional, Pantazis, N, additional, Pelchen‐Matthews, A, additional, Touloumi, G, additional, and Wolf, E, additional
- Published
- 2020
- Full Text
- View/download PDF
13. Effect of incident hepatitis C infection on CD4(+) cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort
- Author
-
van Santen, DK, van der Helm, JJ, Touloumi, G, Pantazis, N, Muga, R, Gunsenheimer-Bartmeyer, B, Gill, MJ, Sanders, E, Kelleher, A, Zangerle, R, Porter, K, Prins, M, Geskus, RB, Del Amo, J, Meyer, L, Bucher, HC, Chene, G, Hamouda, O, Pillay, D, Rosinska, M, Sabin, C, Olson, A, Cartier, A, Fradette, L, Walker, S, Babiker, A, De Luca, A, Fisher, M, Kelleher, T, Cooper, D, Grey, P, Finlayson, R, Bloch, M, Ramacciotti, T, Gelgor, L, Smith, D, Lutsar, I, Dabis, F, Thiebaut, R, Costagliola, D, Guiguet, M, Vanhems, P, Chaix, ML, Ghosn, J, Boufassa, F, Meixenberger, K, Bannert, N, Antoniadou, A, Chrysos, G, Daikos, GL, Katsarou, O, Rezza, G, Dorrucci, M, Monforte, AD, Schuitemaker, H, Sannes, M, Kran, AMB, Tor, J, de Olalla, PG, Cayla, J, Moreno, S, Monge, S, del Romero, J, Perez-Hoyos, S, Sonnerborg, A, Gunthard, H, Scherrer, A, Malyuta, R, Murphy, G, Johnson, A, Phillips, A, Morrison, C, Salata, R, Mugerwa, R, Chipato, T, Price, MA, Gilmour, J, Kamali, A, Karita, E, Burns, F, Giaquinto, C, Grarup, J, Kirk, O, Bailey, H, Anne, AV, Panteleev, A, Thorne, C, Aboulker, JP, Albert, J, Asandi, S, De Wit, S, Reiss, P, Gatell, J, Karpov, I, Ledergerber, B, Lundgren, J, Moller, C, Rakhmanova, A, Rockstroh, J, Sandhu, M, Dedes, N, Fenton, K, Pizzuti, D, Vitoria, M, Faggion, S, Frost, R, Raben, D, Schwimmer, C, and Scott, M
- Subjects
hepatitis C virus ,HIV RNA ,CD4(+) cell count ,HIV ,MSM - Abstract
Background: Most studies on hepatitis C virus (HCV)/HIV-coinfection do not account for the order and duration of these two infections. We aimed to assess the effect of incident HCVinfection, and its timing relative to HIVseroconversion (HIVsc) in HIV-positiveMSM on their subsequent CD4(+) T-cell count and HIV RNA viral load trajectories. Methods: WeincludedMSMwithwell estimated dates ofHIVsc from 17 cohortswithin the CASCADE Collaboration. HCV-coinfected MSM were matched to as many HIV monoinfected MSM as possible by HIV-infection duration and combination antiretroviral therapy (cART) use. We used multilevel random-effects models stratified by cART use to assess differences inCD4(+) cell count andHIVRNAviral loadtrajectoriesbyHCV-coinfection status. Findings: Wematched 214 (ART-naive) and 147 (on cART) HCV-coinfectedMSMto 5384 and 3954, respectively, matched controls. The timing of HCV seroconversion (HCVsc) relative to HIVsc had no demonstrable effect on HIV RNA viral load or CD4(+) cell count trajectories. In the first 2-3 years following HCVsc CD4(+) cell counts were lower among HCV-coinfected MSM, but became comparable with HIV monoinfected MSM thereafter. In ART-naive MSM, during the first 2 years after HCVsc, HIV RNA viral load levels were lower or comparable with HIV monoinfected, tending to be higher thereafter. In MSM on cART, HCV had no significant effect on having a detectable HIV RNA viral load. Interpretation: Irrespective of the duration of HIV infection when HCV is acquired, CD4(+) cell counts were temporarily lower following HCVsc, even when on cART. The clinical implications of our findings remain to be further elucidated. Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
- Published
- 2019
14. Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection
- Author
-
Fidler, S, Olson, AD, Bucher, HC, Fox, J, Thornhill, J, Morrison, C, Muga, R, Phillips, A, Frater, J, Porter, K, Medical Research Council (MRC), St Marys Development Trust, British HIV Association (BHIVA), and Merck Sharp & Dohme Ltd.
- Subjects
Adult ,Male ,Epidemiology ,HIV ,1103 Clinical Sciences ,HIV Infections ,Viral Load ,cure ,Cohort Studies ,Anti-Retroviral Agents ,Withholding Treatment ,Virology ,primary HIV infection ,post treatment control (PTC) ,Humans ,Female ,viral blips - Abstract
Background: Few individuals commencing antiretroviral therapy (ART) in primary HIV infection (PHI) maintain undetectable viremia after treatment cessation. Associated factors remain unclear given the importance of the phenomenon to cure research. Methods: Using CASCADE data of seroconverters starting ART in PHI (≤6 months from seroconversion), we estimated proportions experiencing viral blips (>400 copies followed by 1000 copies per milliliter) and magnitude and frequency of blips while on ART, time from seroconversion to ART, time on ART, adjusting for mean number of HIV-RNA measurements/year while on ART, and other confounders. Results: Seven hundred seventy-eight seroconverters started ART in PHI with ≥3 HIV-RNA measurements. Median interquartile range (IQR) ART duration was 16.2 (8.0-35.9) months, within which we observed 13% with ≥1 blip. Of 228 who stopped ART, 119 rebounded; time to loss of control was associated with longer interval between seroconversion and ART initiation [hazard ratio (HR) = 1.16 per month; 1.04, 1.28], and blips while on ART (HR = 1.71 per blip; 95% confidence interval = 0.94 to 3.10). Longer time on ART (HR = 0.84 per additional month; 0.76, 0.92) was associated with lower risk of losing control. Of 228 stopping ART, 22 (10%) maintained post treatment control (PTC), ie, HIV-RNA Conclusion: HIV viral blips on therapy are associated with subsequent viral rebound on stopping ART among individuals treated in PHI. Longer duration on ART is associated with a greater chance of PTC.
- Published
- 2016
15. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV‐positive people without viral hepatitis in the Swiss HIV Cohort Study.
- Author
-
Kovari, H, Surial, B, Tarr, PE, Cavassini, M, Calmy, A, Schmid, P, Bernasconi, E, Rauch, A, Wandeler, G, Ledergerber, B, Aebi‐Popp, K, Anagnostopoulos, A, Battegay, M, Böni, J, Braun, DL, Bucher, HC, Ciuffi, A, Dollenmaier, G, Egger, M, and Elzi, L
- Subjects
HIV-positive persons ,HIV infections ,STATISTICS ,GENERIC drug substitution ,CONFIDENCE intervals ,TENOFOVIR ,VIRAL hepatitis ,MULTIVARIATE analysis ,NUCLEOSIDE reverse transcriptase inhibitors ,ALANINE aminotransferase ,LONGITUDINAL method - Abstract
Objectives: We previously demonstrated an association between tenofovir disoproxil fumarate (TDF) and chronic liver enzyme elevation in the D:A:D study. The objective of the study was to assess changes in alanine aminotransferase (ALT) levels after switching from TDF to tenofovir alafenamide (TAF). Methods: We included Swiss HIV Cohort Study participants who switched from TDF to TAF with two or more ALT values in the 24 months before and two or more values in the 24 months after replacing TDF with TAF. Individuals with replicating viral hepatitis were excluded. Uni‐ and multivariable linear mixed models were used to explore changes in ALT values associated with switching from TDF to TAF, and to assess potential modifying effects. Results: A total of 1712 participants were included, contributing 6169 ALT values before and 5482 after switching. Median (interquartile range, IQR) age was 50 (42–57) years, and 75% were male. Median (IQR) ALT was 28 (22–38) U/L before and 24 (19–32) U/L after replacing TDF with TAF. ALT values decreased by 3.7 U/L (95% confidence interval: 3.2–4.2) after the switch. The median drop was larger in patients with chronic ALT elevation (defined as two or more elevated values for ≥ 6 months) compared with patients with normal ALT values (17.8 vs. 3.3 U/L, P < 0.001). We did not identify any major effect modifications of the ALT change with any of the potential variables studied. Conclusions: Replacing TDF with TAF in HIV‐monoinfected people led to a significant decrease in ALT values. Findings were not significantly affected by known risk factors for hepatotoxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. ARE ALL CHOLESTEROL LOWERING INTERVENTIONS BENEFICIAL? NEW EVIDENCE FROM A META-ANALYSIS
- Author
-
Bucher, HC and Griffith, L
- Published
- 1996
17. Haben nichtrandomisierte Studien mit kausalen Modellen und randomisierte Studien gleiche Ergebnisse? Eine meta-epidemiologische Studie
- Author
-
Ewald, H, Ioannidis, JP, Ladanie, A, Mc Cord, K, Bucher, HC, Hemkens, LG, Ewald, H, Ioannidis, JP, Ladanie, A, Mc Cord, K, Bucher, HC, and Hemkens, LG
- Published
- 2018
18. Pragmatische randomisierte kontrollierte Studien mit Versichererdaten zur Untersuchung von wichtigen Fragestellungen der Versorgungsforschung
- Author
-
Bucher, HC and Bucher, HC
- Published
- 2017
19. Chronic hepatitis B and C virus infection and risk for non-hodgkin lymphoma in HIV-infected patients: A cohort study
- Author
-
Wang, Q, De Luca, A, Smith, C, Zangerle, R, Sambatakou, H, Bonnet, F, Smit, C, Schommers, P, Thornton, A, Berenguer, J, Peters, L, Spagnuolo, V, Ammassari, A, Antinori, A, Roldan, E, Mussini, C, Miro, J, Konopnicki, D, Fehr, J, Campbell, M, Termote, M, Bucher, H, Puoti, M, Roldan, EQ, Miro, JM, Campbell, MA, Bucher, HC, Wang, Q, De Luca, A, Smith, C, Zangerle, R, Sambatakou, H, Bonnet, F, Smit, C, Schommers, P, Thornton, A, Berenguer, J, Peters, L, Spagnuolo, V, Ammassari, A, Antinori, A, Roldan, E, Mussini, C, Miro, J, Konopnicki, D, Fehr, J, Campbell, M, Termote, M, Bucher, H, Puoti, M, Roldan, EQ, Miro, JM, Campbell, MA, and Bucher, HC
- Abstract
Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear. Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIVinfected patients. Design: Cohort study. Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Patients: HIV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available. Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring. Results: A total of 52 479 treatment-naive patients (1339 [2.6%] with chronic HBV infection and 7506 [14.3%] with HCV infection) were included, of whom 40 219 (77%) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatmentnaive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95% CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients. Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group. Conclusion: In HIV-infected patients receiving ART, chronic coinfection with HBV and HCV is associated with an increased risk for NHL.
- Published
- 2017
20. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: An international cohort study
- Author
-
Podlekareva Daria, N, Efsen Anne Marie, W, Schultze, A, Post Frank, A, Skrahina Alena, M, Panteleev, A, Furrer, H, Miller Robert, F, Losso, M. H, Toibaro, J, Miro Jose, M, Vassilenko, A, Girardi, Enrico, Bruyand, M, Obel, N, Lundgren Jens, D, Mocroft, A, Kirk, O, Karpov, I, Skrahina, A, Klimuk, D, Skrahin, A, Kondratenko, O, Zalutskaya, A, Bondarenko, V, Mitsura, V, Kozorez, E, Tumash, O, Suetnov, O, Paduto, D, Iljina, V, Kummik, T, Bolokadze, N, Mshvidobadze, K, Lanchava, N, Goginashvili, L, Mikiashvili, L, Bablishvili, N, Rozentale, B, Zeltina, I, Janushkevich, I, Caplinskiene, I, Caplinskas, S, Kancauskiene, Z, Podlasin, R, Wiercinska Drapalo, A, Thompson, M, Kozlowska, J, Grezesczuk, A, Bura, M, Knysz, B, Inglot, M, Garlicki, A, Loster, J, Duiculescu, D, Tetradov, S, Rakhmanova, A, Panteleeva, O, Yakovlev, A, Kozlov, A, Tyukalova, A, Vlasova, Y, Trofimov, T, Kyselyova, G, Thorsteinsson, K, Payen, Mc, Kabeya, K, Necsoi, C, Dabis, F, Morlat, P, Dupont, A, Gerard, Y, Bonnal, F, Ceccaldi, J, De Witte, S, Monlun, E, Lataste, P, Chossat, I, Sagette, M, Rickenbach, M, Elzi, L, Battegay, M, Sculier, D, Calmy, A, Cavassini, M, Bruno, A, Bernasconi, E, Hoffmann, M, Vernazza, P, Fehr, J, Weber, R, Aubert, V, Böni, J, Bucher, Hc, Burton Jeangros, C, Dollenmaier, G, Egger, M, Fellay, J, Fux, Ca, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, Hh, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kouyos, R, Kovari, H, Ledergerber, B, Martinetti, G, Martinez de Tejada, B, Metzner, K, Müller, N, Nadal, D, Nicca, D, Pantaleo, G, Rauch, A, Regenass, S, Rudin, C, Schöni Affolter, F, Schmid, P, Schüpbach, J, Speck, R, Tarr, P, Telenti, A, Trkola, A, Yerly, S, Miller, Rf, Vora, N, Cooke, G, Mullaney, S, Wilkins, E, George, V, Collini, P, Dockrell, D, Post, F, Campbell, L, Brum, R, Mabonga, E, Saigal, P, Kegg, S, Ainsworth, J, Waters, A, Dhar, J, Mashonganyika, L, Girardi, E, Rianda, A, Galati, V, Pinnetti, C, Tommasi, C, Lapadula, G, Di Biagio, A, Parisini, A, Carbonara, S, Angarano, G, Purgatorio, M, Matteelli, Alberto, Apostoli, A, Miro, Jm, Manzardo, C, Ligero, C, Gonzalez, J, Martinez Martinez, Ja, Sanchez, F, Knobel, H, Salvadó, M, Lopez Colomes, Jl, Martínez Lacasa, X, Cuchí, E, Falcó, V, Curran, A, Tortola, Mt, Ocaña, I, Vidal, R, Sambeat, Ma, Pomar, V, Coll, P, Pozamczer, D, Saumoy, M, Alcaide, F, Caylà, J, Moreno, A, Millet, Jp, Orcau, A, Fina, L, Romero, A, Roldan, Ll, Iribarren, Ja, Ibarguren, M, Moreno, S, González, A, Miralles, P, Aldámiz Echevarría, T, Losso, M, Gambardella, L, Macias, L, Warley, E, Tavella, S, Messina, O, Gear, O, Laplume, H, Marson, C, Contarelia, J, Michaan, M, Scapellato, P, Alessandro, D, Bartoletti, B, Palmero, D, Elias, C, Cortes, C, Crabtree, B, Gomez, Jl, Hernandez, La, and Badial, F.
- Subjects
Adult ,Male ,0301 basic medicine ,Pediatrics ,medicine.medical_specialty ,Latin Americans ,Tuberculosis ,Anti-HIV Agents ,Epidemiology ,030106 microbiology ,Population ,Infectious Diseases ,Immunology ,Virology ,Antitubercular Agents ,HIV Infections ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Tuberculosis, Multidrug-Resistant ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,Young adult ,Epidemics ,education ,Prospective cohort study ,education.field_of_study ,AIDS-Related Opportunistic Infections ,business.industry ,Mortality rate ,Middle Aged ,medicine.disease ,Europe ,Latin America ,Female ,business ,Developed country ,Demography ,Cohort study - Abstract
Management of tuberculosis in patients with HIV in eastern Europe is complicated by the high prevalence of multidrug-resistant tuberculosis, low rates of drug susceptibility testing, and poor access to antiretroviral therapy (ART). We report 1 year mortality estimates from a multiregional (eastern Europe, western Europe, and Latin America) prospective cohort study: the TB:HIV study.Consecutive HIV-positive patients aged 16 years or older with a diagnosis of tuberculosis between Jan 1, 2011, and Dec 31, 2013, were enrolled from 62 HIV and tuberculosis clinics in 19 countries in eastern Europe, western Europe, and Latin America. The primary endpoint was death within 12 months after starting tuberculosis treatment; all deaths were classified according to whether or not they were tuberculosis related. Follow-up was either until death, the final visit, or 12 months after baseline, whichever occurred first. Risk factors for all-cause and tuberculosis-related deaths were assessed using Kaplan-Meier estimates and Cox models.Of 1406 patients (834 in eastern Europe, 317 in western Europe, and 255 in Latin America), 264 (19%) died within 12 months. 188 (71%) of these deaths were tuberculosis related. The probability of all-cause death was 29% (95% CI 26-32) in eastern Europe, 4% (3-7) in western Europe, and 11% (8-16) in Latin America (p0·0001) and the corresponding probabilities of tuberculosis-related death were 23% (20-26), 1% (0-3), and 4% (2-8), respectively (p0·0001). Patients receiving care outside eastern Europe had a 77% decreased risk of death: adjusted hazard ratio (aHR) 0·23 (95% CI 0·16-0·31). In eastern Europe, compared with patients who started a regimen with at least three active antituberculosis drugs, those who started fewer than three active antituberculosis drugs were at a higher risk of tuberculosis-related death (aHR 3·17; 95% CI 1·83-5·49) as were those who did not have baseline drug-susceptibility tests (2·24; 1·31-3·83). Other prognostic factors for increased tuberculosis-related mortality were disseminated tuberculosis and a low CD4 cell count. 18% of patients were receiving ART at tuberculosis diagnosis in eastern Europe compared with 44% in western Europe and 39% in Latin America (p0·0001); 12 months later the proportions were 67% in eastern Europe, 92% in western Europe, and 85% in Latin America (p0·0001).Patients with HIV and tuberculosis in eastern Europe have a risk of death nearly four-times higher than that in patients from western Europe and Latin America. This increased mortality rate is associated with modifiable risk factors such as lack of drug susceptibility testing and suboptimal initial antituberculosis treatment in settings with a high prevalence of drug resistance. Urgent action is needed to improve tuberculosis care for patients living with HIV in eastern Europe.EU Seventh Framework Programme.
- Published
- 2016
21. Cost-effectiveness of primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation from the Swiss perspective
- Author
-
Ademi, Z, primary, Gloy, V, additional, Glinz, D, additional, Raatz, H, additional, Van, Stiphout, additional, Bucher, HC, additional, and Schwenkglenks, M, additional
- Published
- 2016
- Full Text
- View/download PDF
22. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons
- Author
-
Rotger, M, Glass, Tr, Junier, T, Lundgren, J, Neaton, Jd, Poloni, Es, van 't Wout AB, Lubomirov, R, Colombo, S, Martinez, R, Rauch, A, Günthard, Hf, Neuhaus, J, Wentworth, D, van Manen, D, Gras, La, Schuitemaker, H, Albini, L, Torti, C, Jacobson, Lp, Li, X, Kingsley, La, Carli, F, Guaraldi, G, Ford, Es, Sereti, I, Hadigan, C, Martinez, E, Arnedo, M, Egaña-Gorroño, L, Gatell, Jm, Law, M, Bendall, C, Petoumenos, K, Rockstroh, J, Wasmuth, Jc, Kabamba, K, Delforge, M, De Wit, S, Berger, F, Mauss, S, de Paz Sierra, M, Losso, M, Belloso, Wh, Leyes, M, Campins, A, Mondi, A, De Luca, A, Bernardino, I, Barriuso-Iglesias, M, Torrecilla-Rodriguez, A, Gonzalez-Garcia, J, Arribas, Jr, Fanti, I, Gel, S, Puig, J, Negredo, E, Gutierrez, M, Domingo, P, Fischer, J, Fätkenheuer, G, Alonso-Villaverde, C, Macken, A, Woo, J, Mcginty, T, Mallon, P, Mangili, A, Skinner, S, Wanke, Ca, Reiss, P, Weber, R, Bucher, Hc, Fellay, J, Telenti, A, Tarr, Pe, Vullo, V, Magnificent, Consortium, Insight, Swiss HIV Cohort Study, Mastroianni, C, MAGNIFICENT Consortium, Swiss HIV Cohort Study, INSIGHT, Rotger, M., Glass, TR., Lubomirov, R., Bucher, HC., Telenti, A., Tarr, PE., Junier, T., Poloni, ES., Fellay, J., Colombo, S., Martinez, R., Rauch, A., Weber, R., Günthard, HF., Neuhaus, J., Wentworth, D., Lundgren, J., Neaton, JD., van Manen, D., Gras, AL., Schuitemaker, H., van Wout AB., Reiss, P., Albini, L., Torti, C., Jacobson, LP., Li, X., Kingsley, LA., Carli, F., Guaraldi, G., Ford, ES., Sereti, I., Hadigan, C., Martinez, E., Arnedo-Valero, M., Egaña-Gorroño, L., Gatell, JM., Law, M., Bendall, C., Petoumenos, K., Rockstroh, J., Wasmuth, JC., Kabamba, K., Delforge, M., De Wit, S., Berger, F., Mauss, S., Sierra Mde, P., Losso, M., Belloso, WH., Leyes, M., Campins, A., Mondi, A., De Luca, A., Bernardino, I., Barriuso-Iglesias£££Mónica£££ M., Rodriguez, AT., Garcia, JG., Arribas, JR., Fanti, I., Gel, S., Puig, J., Negredo, E., Gutierrez, M., Domingo, P., Fischer, J., Fätkenheuer, G., Alonso-Villaverde, C., Macken, A., Woo, J., McGinty, T., Mallon, P., Mangili, A., Skinner, S., Wanke, CA., Aubert, V., Barth, J., Battegay, M., Bernasconi, E., Böni, J., Burton-Jeangros, C., Calmy, A., Cavassini, M., Egger, M., Elzi, L., Fehr, J., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Trkola, A., Vernazza, P., Prins, YS., Kuijpers, TW., Scherpbier, HJ., Boer, K., van der Meer JT., Wit, FW., Godfried, MH., van der Poll, T., Nellen, FJ., Lange, JM., Geerlings, SE., van Vugt, M., Vrouenraets, SM., Pajkrt, D., Bos, JC., van der Valk, M., Schreij, G., Lowe, S., Lashof, AO., Pronk, MJ., Bravenboer, B., van der Ende ME., de Vries-Sluijs TE., Schurink, CA., van der Feltz, M., Nouwen, JL., Gelinck, LB., Verbon, A., Rijnders, BJ., van de Ven-de Ruiter ED., Slobbe, L., Haag, D., Kauffmann, RH., Schippers, EF., Groeneveld, PH., Alleman, MA., Bouwhuis, JW., ten Kate RW., Soetekouw, R., Kroon, FP., van den Broek PJ., van Dissel JT., Arend, SM., van Nieuwkoop, C., de Boer MJ., Jolink, H., den Hollander JG., Pogany, K., Bronsveld, W., Kortmann, W., van Twillert, G., van Houte DP., Polée, MB., van Vonderen MG., ten Napel CH., Kootstra, GJ., Brinkman, K., Blok, WL., Frissen, PH., Schouten, WE., van den Berk GE., Juttmann, JR., van Kasteren ME., Brouwer, AE., Mulder, JW., van Gorp EC., Smit, PM., Weijer, S., van Eeden, A., Verhagen, DW., Sprenger, HG., Doedens, R., Scholvinck, EH., van Assen, S., Stek, CJ., Hoepelman, IM., Mudrikova, T., Schneider, MM., Jaspers, CA., Ellerbroek, PM., Peters, EJ., Maarschalk-Ellerbroek, LJ., Oosterheert, JJ., Arends, JE., Wassenberg, MW., van der Hilst JC., Richter, C., van der Berg JP., Gisolf, EH., Margolick, JB., Plankey, M., Crain, B., Dobs, A., Farzadegan, H., Gallant, J., Johnson-Hill, L., Sacktor, N., Selnes, O., Shepard, J., Thio, C., Phair, JP., Wolinsky, SM., Badri, S., Conover, C., O'Gorman, M., Ostrow, D., Palella, F., Ragin, A., Detels, R., Martínez-Maza, O., Aronow, A., Bolan, R., Breen, E., Butch, A., Fahey, J., Jamieson, B., Miller, EN., Oishi, J., Vinters, H., Visscher, BR., Wiley, D., Witt, M., Yang, O., Young, S., Zhang, ZF., Rinaldo, CR., Becker, JT., Cranston, RD., Martinson, JJ., Mellors, JW., Silvestre, AJ., Stall, RD., Muñoz, A., Abraham, A., Althoff, K., Cox, C., D'Souza, G., Gange, SJ., Golub, E., Schollenberger, J., Seaberg, EC., Su, S., Huebner, RE., Dominguez, G., Moroni, M., Angarano, G., Antinori, A., Carosi, G., Cauda, R., Monforte£££A d'Arminio£££ A., Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Perno, CF., Sagnelli, E., Viale, PL., Von Schlosser, F., d'Arminio Monforte, A., Ammassari, A., Andreoni, M., Balotta, C., Bonfanti, P., Bonora, S., Borderi, M., Capobianchi, MR., Castagna, A., Ceccherini-Silberstein, F., Cozzi-Lepri, A., Gargiulo, M., Gervasoni, C., Girardi, E., Lichtner, M., Lo Caputo, S., Madeddu, G., Maggiolo, F., Marcotullio, S., Monno, L., Murri, R., Mussini, C., Puoti, M., Formenti, T., Galli, L., Lorenzini, P., Montroni, M., Giacometti, A., Costantini, A., Riva, A., Tirelli, U., Martellotta, F., Ladisa, N., Lazzari, G., Verucchi, G., Castelli, F., Scalzini, A., Minardi, C., Bertelli, D., Quirino, T., Abeli, C., Manconi, PE., Piano, P., Vecchiet, J., Falasca, K., Carnevale, G., Lorenzotti, S., Sighinolfi, L., Segala, D., Leoncini, F., Mazzotta, F., Pozzi, M., Cassola, G., Viscoli, G., Viscoli, A., Piscopo, R., Mazzarello, G., Mastroianni, C., Belvisi, V., Caramma, I., Chiodera, A., Castelli, P., Rizzardini, G., Ridolfo, AL., Foschi, A., Salpietro, S., Galli, A., Bigoloni, A., Spagnuolo, V., Merli, S., Carenzi, L., Moioli, MC., Cicconi, P., Bisio, L., Gori, A., Lapadula, G., Abrescia, N., Chirianni, A., De Marco, M., Ferrari, C., Borghi, R., Baldelli, F., Belfiori, B., Parruti, G., Ursini, T., Magnani, G., Ursitti, MA., Narciso, P., Tozzi, V., Vullo, V., d'Avino, A., Zaccarelli, M., Gallo, L., Acinapura, R., Capozzi, M., Libertone, R., Trotta, MP., Tebano, G., Cattelan, AM., Mura, MS., Caramello, P., Orofino, GC., Sciandra, M., Raise, Ebo, F., Pellizzer, G., Manfrin, V., McManus, H., Wright, S., Moore, R., Edwards, S., Medische Microbiologie, RS: CAPHRI School for Public Health and Primary Care, AII - Amsterdam institute for Infection and Immunity, Experimental Immunology, Other departments, Graduate School, APH - Amsterdam Public Health, Global Health, Medical Microbiology and Infection Prevention, Paediatric Infectious Diseases / Rheumatology / Immunology, Other Research, Obstetrics and Gynaecology, Infectious diseases, General Internal Medicine, Center of Experimental and Molecular Medicine, University of Zurich, Tarr, Philip E, Rotger, M, Glass, T, Junier, T, Lundgren, J, Neaton, J, Poloni, E, Van 'T Wout, A, Lubomirov, R, Colombo, S, Martinez, R, Rauch, A, Günthard, H, Neuhaus, J, Wentworth, D, Van Manen, D, Gras, L, Schuitemaker, H, Albini, L, Torti, C, Jacobson, L, Li, X, Kingsley, L, Carli, F, Guaraldi, G, Ford, E, Sereti, I, Hadigan, C, Martinez, E, Arnedo, M, Egaña Gorroño, L, Gatell, J, Law, M, Bendall, C, Petoumenos, K, Rockstroh, J, Wasmuth, J, Kabamba, K, Delforge, M, De Wit, S, Berger, F, Mauss, S, De Paz Sierra, M, Losso, M, Belloso, W, Leyes, M, Campins, A, Mondi, A, De Luca, A, Bernardino, I, Barriuso Iglesias, M, Torrecilla Rodriguez, A, Gonzalez Garcia, J, Arribas, J, Fanti, I, Gel, S, Puig, J, Negredo, E, Gutierrez, M, Domingo, P, Fischer, J, Fätkenheuer, G, Alonso Villaverde, C, Macken, A, Woo, J, Mcginty, T, Mallon, P, Mangili, A, Skinner, S, Wanke, C, Reiss, P, Weber, R, Bucher, H, Fellay, J, Telenti, A, Tarr, P, Gori, A, Junier, Thomas, Poloni, Estella S., Rotger, Margalida, Glass, Tracy R., Junier, Thoma, Lundgren, Jen, Neaton, James D., Van 't Wout, Angã©lique B., Lubomirov, Rubin, Colombo, Sara, Martinez, Raquel, Rauch, Andri, Gã¼nthard, Huldrych F., Neuhaus, Jacqueline, Wentworth, Deborah, Van Manen, Danielle, Gras, Luuk A., Schuitemaker, Hanneke, Albini, Laura, Torti, Carlo, Jacobson, Lisa P., Li, Xiuhong, Kingsley, Lawrence A., Carli, Federica, Guaraldi, Giovanni, Ford, Emily S., Sereti, Irini, Hadigan, Colleen, Martinez, Esteban, Arnedo, Mireia, Egaã±a gorroã±o, Lander, Gatell, Jose M., Law, Matthew, Bendall, Courtney, Petoumenos, Kathy, Rockstroh, Jã¼rgen, Wasmuth, Jan christian, Kabamba, Kabeya, Delforge, Marc, De Wit, Stephane, Berger, Florian, Mauss, Stefan, De Paz Sierra, Mariana, Losso, Marcelo, Belloso, Waldo H., Leyes, Maria, Campins, Antoni, Mondi, Annalisa, De Luca, Andrea, Bernardino, Ignacio, Barriuso iglesias, Mã³nica, Torrecilla rodriguez, Ana, Gonzalez garcia, Juan, Arribas, Josã© R., Fanti, Iuri, Gel, Silvia, Puig, Jordi, Negredo, Eugenia, Gutierrez, Mar, Domingo, Pere, Fischer, Julia, Fã¤tkenheuer, Gerd, Alonso villaverde, Carlo, Macken, Alan, Woo, Jame, Mcginty, Tara, Mallon, Patrick, Mangili, Alexandra, Skinner, Sally, Wanke, Christine A., Reiss, Peter, Weber, Rainer, Bucher, Heiner C., Fellay, Jacque, Telenti, Amalio, Tarr, Philip E. Swiss Hiv Cohort, and Castagna, Antonella
- Subjects
Male ,HIV Infections ,Genome-wide association study ,030204 cardiovascular system & hematology ,2726 Microbiology (medical) ,10234 Clinic for Infectious Diseases ,Coronary artery disease ,0302 clinical medicine ,ddc:590 ,Risk Factors ,Abacavir ,80 and over ,genetics ,030212 general & internal medicine ,Family history ,Articles and Commentaries ,Aged, 80 and over ,education.field_of_study ,medicine.diagnostic_test ,traditional risk factor ,Single Nucleotide ,Middle Aged ,3. Good health ,Infectious Diseases ,traditional risk factors ,Cohort ,Female ,HIV infection ,antiretroviral therapy ,coronary artery disease ,Human ,medicine.drug ,Adult ,Microbiology (medical) ,medicine.medical_specialty ,Adolescent ,Population ,Infectious Disease ,610 Medicine & health ,Polymorphism, Single Nucleotide ,Genetic Predisposition to Disease ,Aged ,Coronary Artery Disease ,Humans ,Polymorphism ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,education ,Genetic testing ,business.industry ,Risk Factor ,2725 Infectious Diseases ,Odds ratio ,medicine.disease ,Immunology ,genetic ,business - Abstract
BACKGROUND: Persons infected with human immunodeficiency virus (HIV) have increased rates of coronary artery disease (CAD). The relative contribution of genetic background, HIV-related factors, antiretroviral medications, and traditional risk factors to CAD has not been fully evaluated in the setting of HIV infection.METHODS: In the general population, 23 common single-nucleotide polymorphisms (SNPs) were shown to be associated with CAD through genome-wide association analysis. Using the Metabochip, we genotyped 1875 HIV-positive, white individuals enrolled in 24 HIV observational studies, including 571 participants with a first CAD event during the 9-year study period and 1304 controls matched on sex and cohort.RESULTS: A genetic risk score built from 23 CAD-associated SNPs contributed significantly to CAD (P = 2.9 × 10(-4)). In the final multivariable model, participants with an unfavorable genetic background (top genetic score quartile) had a CAD odds ratio (OR) of 1.47 (95% confidence interval [CI], 1.05-2.04). This effect was similar to hypertension (OR = 1.36; 95% CI, 1.06-1.73), hypercholesterolemia (OR = 1.51; 95% CI, 1.16-1.96), diabetes (OR = 1.66; 95% CI, 1.10-2.49), ≥ 1 year lopinavir exposure (OR = 1.36; 95% CI, 1.06-1.73), and current abacavir treatment (OR = 1.56; 95% CI, 1.17-2.07). The effect of the genetic risk score was additive to the effect of nongenetic CAD risk factors, and did not change after adjustment for family history of CAD.CONCLUSIONS: In the setting of HIV infection, the effect of an unfavorable genetic background was similar to traditional CAD risk factors and certain adverse antiretroviral exposures. Genetic testing may provide prognostic information complementary to family history of CAD.
- Published
- 2013
- Full Text
- View/download PDF
23. Increasing Access to Hepatitis C Treatment in Rwanda: The Promise of RwandaâÂÂs Existing HIV Infrastructure
- Author
-
Bucher Hc, Uwizihiwe Jp, Nsanzimana S, and Kirk Cm
- Subjects
medicine.medical_specialty ,business.industry ,Family medicine ,Human immunodeficiency virus (HIV) ,medicine ,Hepatitis C ,Omics ,medicine.disease_cause ,medicine.disease ,Bioinformatics ,business - Published
- 2015
- Full Text
- View/download PDF
24. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for > 3 Years With Incomplete CD4 Recovery
- Author
-
Engsig, FN, Zangerle, R, Katsarou, O, Dabis, F, Reiss, P, Gill, J, Porter, K, Sabin, C, Riordan, A, Fatkenheuer, G, Gutierrez, F, Raffi, F, Kirk, O, Mary-Krause, M, Stephan, C, de Olalla, PG, Guest, J, Samji, H, Castagna, A, Monforte, AD, Skaletz-Rorowski, A, Ramos, J, Lapadula, G, Mussini, C, Force, L, Meyer, L, Lampe, F, Boufassa, F, Bucher, HC, De Wit, S, Burkholder, GA, Teira, R, Justice, AC, Sterling, TR, Crane, HM, Gerstoft, J, Grarup, J, May, M, Chene, G, Ingle, SM, Sterne, J, and Obel, N
- Subjects
HIV ,risk factors ,sustained viral suppression ,mortality ,CD4 cell recovery - Abstract
Background. Some human immunodeficiency virus (HIV)-infected individuals initiating combination antiretroviral therapy (cART) with low CD4 counts achieve viral suppression but not CD4 cell recovery. We aimed to identify (1) risk factors for failure to achieve CD4 count >200 cells/mu L after 3 years of sustained viral suppression and (2) the association of the achieved CD4 count with subsequent mortality. Methods. We included treated HIV-infected adults from 2 large international HIV cohorts, who had viral suppression (3 years with CD4 count 200 cells/mu L after 3 years of suppression. Increasing age, lower initial CD4 count, male heterosexual and injection drug use transmission, cART initiation after 1998, and longer time from initiation of cART to start of the virally suppressed period were risk factors for not achieving a CD4 count >200 cells/mu L. Individuals with CD4 200 cells/mu L. The increased mortality was seen across different patient groups and for all causes of death. Conclusions. Virally suppressed HIV-positive individuals on cART who do not achieve a CD4 count >200 cells/mu L have substantially increased long-term mortality.
- Published
- 2014
25. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study
- Author
-
Kamara, David A., Ryom, Lene, Ross, Michael, Kirk, Ole, Reiss, Peter, Morlat, Philippe, Moranne, Olivier, Fux, Christoph A., Mocroft, Amanda, Sabin, Caroline, Lundgren, Jens D., Smith, Colette J, D:A:D study, Group., Quiros, Roldan, Powderly B, M. E., Shortman, N, Moecklinghoff, C, Reilly, G, Franquet, X, Ryom, L, Sabin, Ca, Kamara, D, Smith, C, Phillips, A, Mocroft, A, Tverland, J, Mansfeld, M, Nielsen, J, Raben, D, Lundgren, Jd, Brandt, R, Rickenbach, M, Fanti, I, Krum, E, Hillebregt, M, Geffard, S, Sundström, A, Delforge, M, Fontas, E, Torres, F, Mcmanus, H, Wright, S, Kjær, J, Sjøl, A, Meidahl, P, Helweg-Larsen, J, Iversen, J, Kirk, O, Reiss, P, Ross, M, Fux, Ca, Morlat, P, Moranne, O, Kesselring, Am, Kamara, Da, Weber, R, Pradier, C, Friis-Møller, N, Kowalska, J, Sabin, C, Law, M, d'Arminio Monforte, A, Dabis, F, Bruyand, M, Bower, M, Fätkenheuer, G, Donald, A, Grulich, A, Zaheri, S, Gras, L, Prins, Jm, Kuijpers, Tw, Scherpbier, Hj, van der Meer JT, Wit, Fw, Godfried, Mh, van der Poll, D, Nellen, Fj, Lange, Jm, Geerlings, Se, van Vugt, M, Pajkrt, D, Bos, D, van der Valk, D, Grijsen, Ml, Wiersinga, Wj, Goorhuis, A, Hovius, Jw, Lowe, S, Lashof, A, Posthouwer, D, Ammerlaan, Hs, Pronk, Mj, van der Ende ME, de Vries-Sluijs TE, Schurink, Ca, Nouwen, Jl, Verbon, A, Rijnders, Bj, van Gorp EC, van der Feltz, M, Driessen, Gj, van Rossum AM, Branger, J, Schippers, F, van Nieuwkoop, C, van Elzakker EP, Groeneveld, Ph, Bouwhuis, Jw, Soetekouw, R, ten Kate RW, Kroon, Fp, van Dissel JT, Arend, Sm, de Boer MG, Jolink, H, ter Vollaard HJ, Bauer, Mp, den Hollander JG, Pogany, K, van Twillert, D, Kortmann, W, Stuart, Jw, Diederen, Bm, Leyten, Ms, Gelinck, Lb, Kootstra, Gj, Delsing, Ce, Brinkman, K, Blok, Wl, Frissen, Ph, Schouten, We, van den Berk GE, van Kasteren ME, Brouwer, Ae, Veenstra, J, Lettinga, Kd, Mulder, Jw, Vrouenraets, Sm, Lauw, Fn, van Eeden, A, Verhagen, Dw, Sprenger, Hg, Doedens, R, Scholvinck, Eh, van Assen, S, Bierman, Wf, Koopmans, Pp, Keuter, M, van der Ven AJ, ter Hofstede HJ, Dofferhoff, As, Warris, A, van Crevel, R, Hoepelman, Ai, Mudrikova, T, Schneider, Mm, Ellerbroek, Pm, Oosterheert, Jj, Arends, Je, Wassenberg, Mw, Barth, Re, van Agtmael, M, Perenboom, Rm, Claessen, Fa, Bomers, M, Peters, Ej, Geelen, Sp, Wolfs, Tf, Bont, Lj, Richter, C, van der Berg JP, Gisolf, Eh, van den Berge, M, Stegeman, A, van Vonderen MG, van Houte DP, Weijer, S, el Moussaoui, R, Winkel, C, Muskiet, F, Durand, Voigt, R, Chêne, G, Lawson-Ayayi, S, Thiébaut, R, Bonnal, F, Bonnet, F, Bernard, N, Caunègre, L, Cazanave, C, Ceccaldi, J, Chambon, D, Chossat, I, Dauchy, Fa, De Witte, S, Dupon, M, Duffau, P, Dutronc, H, Farbos, S, Gaborieau, V, Gemain, Mc, Gerard, Y, Greib, C, Hessamfar, M, Lacoste, D, Lataste, P, Lafarie, S, Lazaro, E, Malvy, D, Meraud, Jp, Mercié, P, Monlun, E, Neau, D, Ochoa, A, Pellegrin, Jl, Pistone, T, Ragnaud, Jm, Receveur, Mc, Tchamgoué, S, Vandenhende, Ma, Viallard, Jf, Moreau, Jf, Pellegrin, I, Fleury, H, Lafon, Me, Masquelier, B, Trimoulet, P, Breilh, D, Haramburu, F, Miremont-Salamé, G, Blaizeau, Mj, Decoin, M, Delaune, J, Delveaux, S, D'Ivernois, C, Hanapier, C, Leleux, O, Uwamaliya-Nziyumvira, B, Sicard, X, Palmer, G, Touchard, D, Petoumenos, K, Bendall, C, Moore, R, Edwards, S, Hoy, J, Watson, K, Roth, N, Nicholson, J, Bloch, M, Franic, T, Baker, D, Vale, R, Carr, A, Cooper, D, Chuah, J, Ngieng, M, Nolan, D, Skett, J, Calvo, G, Mateu, S, Domingo, P, Sambeat, Ma, Gatell, J, Del Cacho, E, Cadafalch, J, Fuster, M, Codina, C, Sirera, G, Vaqué, A, De Wit, S, Clumeck, N, Necsoi, C, Gennotte, Af, Gerard, M, Kabeya, K, Konopnicki, D, Libois, A, Martin, C, Payen, Mc, Semaille, P, Van Laethem, Y, Neaton, J, Bartsch, G, El-Sadr, Wm, Thompson, G, Wentworth, D, Luskin-Hawk, R, Telzak, E, Abrams, Di, Cohn, D, Markowitz, N, Arduino, R, Mushatt, D, Friedland, G, Perez, G, Tedaldi, E, Fisher, E, Gordin, F, Crane, Lr, Sampson, J, Baxter, J, Lundgren, J, Cozzi-Lepri, A, Grint, D, Podlekareva, D, Peters, L, Reekie, J, Fischer, Ah, Losso, M, Elias, C, Vetter, N, Zangerle, R, Karpov, I, Vassilenko, A, Mitsura, Vm, Suetnov, O, Colebunders, R, Vandekerckhove, L, Hadziosmanovic, V, Kostov, K, Machala, L, Begovac, J, Jilich, D, Sedlacek, D, Kronborg, G, Gerstoft, J, Benfield, T, Larsen, M, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Ostergaard, L, Zilmer, K, Smidt, J, Ristola, M, Katlama, C, Viard, J, Girard, P, Livrozet, Jm, Vanhems, P, Rockstroh, J, Schmidt, R, van Lunzen, J, Degen, O, Stellbrink, Hj, Staszewski, S, Bickel, M, Kosmidis, J, Gargalianos, P, Xylomenos, G, Perdios, J, Panos, G, Filandras, A, Karabatsaki, E, Sambatakou, H, Banhegyi, D, Mulcahy, F, Yust, I, Turner, D, Burke, M, Pollack, S, Hassoun, G, Maayan, S, Vella, S, Esposito, R, Mazeu, I, Mussini, C, Arici, C, Pristera, R, Mazzotta, F, Gabbuti, A, Vullo, V, Lichtner, M, Chirianni, A, Montesarchio, E, Gargiulo, M, Antonucci, G, Testa, A, Narciso, P, Vlassi, C, Zaccarelli, M, Lazzarin, A, Castagna, A, Gianotti, N, Galli, M, Ridolfo, A, Rozentale, B, Zeltina, I, Chaplinskas, S, Hemmer, R, Staub, T, Ormaasen, V, Maeland, A, Bruun, J, Knysz, B, Gasiorowski, J, Horban, A, Bakowska, E, Grzeszczuk, A, Flisiak, R, Boron-Kaczmarska, A, Pynka, M, Parczewski, M, Beniowski, M, Mularska, E, Trocha, H, Jablonowska, E, Malolepsza, E, Wojcik, K, Antunes, F, Doroana, M, Caldeira, L, Mansinho, K, Maltez, F, Duiculescu, D, Rakhmanova, A, Babes, V, Zakharova, N, Jevtovic, D, Mokráš, M, Staneková, D, Tomazic, J, González-Lahoz, J, Soriano, V, Labarga, P, Medrano, J, Moreno, S, Rodriguez, Jm, Clotet, B, Jou, A, Paredes, R, Tural, C, Puig, J, Bravo, I, Gatell, Jm, Miró, Jm, Gutierrez, M, Karlsson, A, Mateo, G, Flamholc, L, Ledergerber, B, Francioli, P, Cavassini, M, Hirschel, B, Boffi, E, Kravchenko, E, Furrer, H, Battegay, M, Elzi, L, Chentsova, N, Frolov, V, Kutsyna, G, Servitskiy, S, Krasnov, M, Barton, S, Johnson, Am, Mercey, D, Johnson, Ma, Murphy, M, Weber, J, Scullard, G, Fisher, M, Leen, C, Morfeldt, L, Thulin, G, Åkerlund, B, Koppel, K, Håkangård, C, Moroni, M, Angarano, G, Antinori, A, Armignacco, O, Castelli, F, Cauda, R, Di Perri, G, Iardino, R, Ippolito, G, Perno, Cf, von Schloesser, F, Viale, P, Ceccherini-Silberstein, F, Girardi, E, Lo Caputo, S, Puoti, M, Andreoni, M, Ammassari, A, Balotta, C, Bonfanti, P, Bonora, S, Borderi, M, Capobianchi, Mr, Cingolani, A, Cinque, P, De Luca, A, Di Biagio, A, Gori, A, Guaraldi, G, Lapadula, G, Madeddu, G, Maggiolo, F, Marchetti, G, Marcotullio, S, Monno, L, Quiros, E, Rusconi, S, Cicconi, P, Formenti, T, Galli, L, Lorenzini, P, Giacometti, A, Costantini, A, Santoro, C, Suardi, C, Vanino, E, Verucchi, G, Quiros Roldan, E, Minardi, C, Quirino, T, Abeli, C, Manconi, Pe, Piano, P, Vecchiet, J, Falasca, K, Sighinolfi, L, Segala, D, Cassola, G, Viscoli, G, Alessandrini, A, Piscopo, R, Mazzarello, G, Mastroianni, C, Belvisi, V, Caramma, I, Castelli, Ap, Rizzardini, G, Ridolfo, Al, Piolini, R, Salpietro, S, Carenzi, L, Moioli, Mc, Puzzolante, C, Onofrio, M, Abrescia, N, Guida, Mg, Baldelli, F, Francisci, D, Parruti, G, Ursini, T, Magnani, G, Ursitti, Ma, d' Avino, A, Gallo, L, Nicastri, E, Acinapura, R, Capozzi, M, Libertone, R, Tebano, G, Cattelan, A, Mura, Ms, Caramello, P, Orofino, Gc, Sciandra, M, Pellizzer, G, Manfrin, V, Caissotti, C, Dellamonica, P, Bernard, E, Cua, E, De Salvador- Guillouet, F, Durant, J, Ferrando, S, Mondain-Miton, V, Naqvi, A, Perbost, I, Prouvost-Keller, B, Pillet, S, Pugliese, P, Rahelinirina, V, Roger, Pm, Dollet, K, Aubert, V, Barth, J, Bernasconi, E, Böni, J, Bucher, Hc, Burton- Jeangros, C, Calmy, A, Egger, M, Fehr, J, Fellay, J, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, Hh, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kovari, H, Martinetti, G, de Tejada BM, Metzner, K, Müller, N, Nadal, D, Pantaleo, G, Rauch, A, Regenass, A, Rudin, C, Schmid, P, Schultze, D, Schöni-Affolter, F, Schüpbach, J, Speck, R, Taffé, P, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Yerly, S., AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, Global Health, Other departments, Infectious diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, General Internal Medicine, Dermatology, Medical Microbiology and Infection Prevention, Sea to Shore Alliance, University of Florida [Gainesville] (UF), Observatoire des Micro et Nano Technologies (OMNT - UMS 2920), Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Structures et propriétés d'architectures moléculaire (SPRAM - UMR 5819), Institut Nanosciences et Cryogénie (INAC), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Service de médecine interne et maladies infectieuses [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Département de santé publique, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital Larchet, Service de néphrologie, Hôpital Pasteur [Nice] (CHU)-Centre Hospitalier Universitaire de Nice (CHU Nice), Department of primary care and population sciences, University College of London [London] (UCL), Research Department of Infection and Population Health [London], Economics, Umeå University, Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Institut Nanosciences et Cryogénie (INAC), and Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])
- Subjects
Adult ,Male ,CHRONIC KIDNEY-DISEASE ,Internationality ,FUNCTION DECLINE ,diagnosis ,nephrology ,Chronic kidney disease ,Estimated glomerular filtration rate ,HIV ,Kidney disease ,Rapid progression ,D:A:D study Group ,HIV Infections ,urologic and male genital diseases ,Sensitivity and Specificity ,Severity of Illness Index ,GLOMERULAR-FILTRATION-RATE ,renal insufficiency ,NO ,MORTALITY RISK ,ANTIRETROVIRAL THERAPY ,80 and over ,Humans ,chronic kidney disease ,estimated glomerular filtration rate ,hiv ,kidney disease ,rapid progression ,adult ,aged ,aged, 80 and over ,diagnosis, computer-assisted ,disease progression ,female ,glomerular filtration rate ,hiv infections ,humans ,internationality ,male ,middle aged ,renal insufficiency, chronic ,reproducibility of results ,sensitivity and specificity ,algorithms ,severity of illness index ,Diagnosis, Computer-Assisted ,Renal Insufficiency, Chronic ,ComputingMilieux_MISCELLANEOUS ,BODY-SURFACE AREA ,POPULATION ,Aged ,Aged, 80 and over ,INFECTED PATIENTS ,Reproducibility of Results ,1103 Clinical Sciences ,ASSOCIATION ,Urology & Nephrology ,Middle Aged ,chronic ,INDIVIDUALS ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,computer-assisted ,Disease Progression ,Female ,Algorithms ,Research Article ,Glomerular Filtration Rate - Abstract
BACKGROUND: No consensus exists on how to define abnormally rapid deterioration in renal function (Rapid Progression, RP). We developed an operational definition of RP in HIV-positive persons with baseline estimated glomerular filtration rate (eGFR) >90 ml/min/1.73 m2 (using Cockcroft Gault) in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study from 2004 to 2011. METHODS: Two definitions were evaluated; RP definition A: An average eGFR decline (slope) ≥5 ml/min/1.73 m2/year over four years of follow-up with ≥3 eGFR measurements/year, last eGFR
- Published
- 2014
26. Missed opportunities among HIV-positive women to control viral replication during pregnancy and to have a vaginal delivery
- Author
-
Aebi Popp, K, Mulcahy, F, Glass, Tr, Rudin, C, Martinez de Tejada, B, Bertisch, B, Fehr, J, Grawe, C, Scheibner, K, Rickenbach, M, Hoesli, I, Thorne, C, European Collaborative Study in EuroCoord, Swiss, Mother, Child HIV Cohort Study Collaborators: Thorne, C, Bailey, H, Giaquinto, C, Rampon, O, Mazza, A, De Rossi, A, Wörner, I, Mok, J, de José MI, Martínez, B, Peña, J, Garcia, J, Lopez, Jr, Rodriguez, Mc, Asensi Botet, F, Otero, Mc, Pérez Tamarit, D, Scherpbier, Hj, Kreyenbroek, M, Godfried, Mh, Nellen, Fj, Boer, K, Navér, L, Bohlin, Ab, Lindgren, S, Kaldma, A, Belfrage, E, Levy, J, Barlow, P, Manigart, Y, Hainaut, M, Goetghebuer, T, Brichard, B, De Camps, J, Thiry, N, Deboone, G, Waterloos, H, Viscoli, C, De Maria, A, Bentivoglio, G, Ferrero, S, Gotta, C, Mûr, A, Payà, A, López Vilchez MA, Carreras, R, Valerius, Nh, Rosenfeldt, V, Coll, O, Suy, A, Perez, J, Fortuny, C, Boguña, J, Savasi, V, Fiore, S, Crivelli, M, Viganò, A, Giacomet, V, Cerini, C, Raimondi, C, Zuccotti, G, Alberico, S, Maso, G, Tropea, M, Barresi, V, Taylor, G, Lyall, Eg, Penn, Z, Buffolano, W, Tiseo, R, Martinelli, P, Sansone, M, Maruotti, G, Agangi, A, Tibaldi, C, Marini, S, Masuelli, G, Benedetto, Chiara, Niemieç, T, Marczynska, M, Dobosz, S, Popielska, J, Oldakowska, A, Aubert, V, Barth, J, Battegay, M, Bernasconi, E, Böni, J, Brazzola, P, Bucher, Hc, Burton Jeangros, C, Calmy, A, Cavassini, M, Cheseaux, Jj, Drack, G, Duppenthaler, A, Egger, M, Elzi, L, Fellay, J, Francini, K, Furrer, H, Fux, Ca, Gorgievski, M, Günthard, H, Haerry, D, Hasse, B, Hirsch, Hh, Hösli, I, Kahlert, C, Kaiser, L, Keiser, O, Klimkait, T, Kovari, H, Ledergerber, B, Martinetti, G, de Tejada, B, Metzner, K, Müller, N, Nadal, D, Pantaleo, G, Polli, Ch, Posfay Barbe, K, Rauch, A, Regenass, S, Schmid, P, Schultze, D, Schöni Affolter, F, Schüpbach, J, Speck, R, Taffé, P, Tarr, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Wyler, Ca, Yerly, S., Posfay Barbe, Klara, Wyler, Claire-Anne, University of Zurich, Aebi-Popp, Karoline, Aebi Popp, K, Mulcahy, F, Glass, Tr, Rudin, C, Martinez de Tejada, B, Bertisch, B, Fehr, J, Grawe, C, Scheibner, K, Rickenbach, M, Hoesli, I, Buffolano, Wilma, Thorne, C, European Collaborative Study in, Eurocoord, Swiss, Mother, and Child HIV Cohort, S. t. u. d. y.
- Subjects
mode of delivery ,medicine.medical_treatment ,HIV Infections ,Delivery, Obstetric/statistics & numerical data ,Virus Replication ,10234 Clinic for Infectious Diseases ,Cohort Studies ,HIV Infections/drug therapy/prevention & control/transmission ,Pregnancy ,Antiretroviral Therapy, Highly Active ,2736 Pharmacology (medical) ,Pharmacology (medical) ,Surgical Procedures, Elective/statistics & numerical data ,Pregnancy Complications, Infectious ,Europe ,HIV ,Mode of delivery ,Adult ,Anti-HIV Agents ,Cesarean Section ,Delivery, Obstetric ,Drug Therapy, Combination ,Elective Surgical Procedures ,Female ,Guidelines as Topic ,Health Policy ,Humans ,Infant, Newborn ,Infectious Disease Transmission, Vertical ,Viral Load ,Infectious Diseases ,ddc:618 ,Obstetrics ,Vaginal delivery ,Transmission (medicine) ,Cesarean Section/statistics & numerical data ,Meta-analysis ,provvedimento amministrativo - nullità - domanda riconvenzionale ,Viral load ,Cohort study ,medicine.medical_specialty ,Pregnancy Complications, Infectious/drug therapy/epidemiology/prevention & control ,610 Medicine & health ,Europe/epidemiology ,Pharmacotherapy ,medicine ,Caesarean section ,business.industry ,2725 Infectious Diseases ,medicine.disease ,Viral Load/drug effects ,HIV, pregnancy, mode of delivery ,Anti-HIV Agents/therapeutic use ,Settore MED/40 - Ginecologia e Ostetricia ,business ,Infectious Disease Transmission, Vertical/prevention & control/statistics & numerical data - Abstract
INTRODUCTION: Most national guidelines for the prevention of mother-to-child transmission of HIV in Europe updated between 2001 and 2010 recommend vaginal deliveries for women with undetectable or very low viral load (VL). Our aim was to explore the impact of these new guidelines on the rates of vaginal deliveries among HIV-positive women in Europe. METHODS: In a pooled analysis of data on HIV-positive pregnant women enrolled in the Swiss Mother & Child HIV Cohort Study and the European Collaborative Study 2000 to 2010, deliveries were classified as occurring pre- or postpublication of national guidelines recommending vaginal delivery. RESULTS: Overall, 2663 women with 3013 deliveries were included from 10 countries; 28% women were diagnosed with HIV during pregnancy. Combination antiretroviral therapy was used in most pregnancies (2020, 73%), starting during the first or second trimester in 78% and during the third trimester in 22%; in 25% pregnancies, the woman conceived on combination antiretroviral therapy. Overall, in 86% pregnancies, a VL < 400 copies per milliliter was achieved before delivery. The proportion of vaginal deliveries increased from 17% (414/2377) before the change in guidelines to 52% (313/600) after; elective Caesarean section rates decreased from 65% to 27%. The proportion of women with undetectable VL having a Caesarean section was 55% after implementation of new guidelines. We observed a decrease of late preterm deliveries from 16% (377/2354) before to 7% (42/599) after the change in guidelines (P < 0.001). CONCLUSION: There are still missed opportunities for women with HIV to fully suppress their VL and to deliver vaginally in Europe.
- Published
- 2013
27. Expansion of interferon-γ-secreting HIV-specific T cells during successful antiretroviral therapy
- Author
-
Gasser, O, Brander, C, Wolbers, M, Brown, NV, Rauch, A, Günthard, HF, Battegay, M, Hess, C, Bernasconi, E, Böni, J, Bucher, HC, Bürgisser, P, Calmy, A, Cattacin, S, Cavassini, M, Dubs, R, Egger, M, Elzi, L, Fischer, M, Flepp, M, Fontana, A, Francioli, P, Furrer, H, Fux, CA, Gorgievski, M, Günthard, H, Hirsch, HH, Hirschel, B, Hösli, I, Kahlert, C, Kaiser, L, Karrer, U, Kind, C, Klimkait, T, Ledergerber, B, Martinetti, G, Müller, N, Nadal, D, Paccaud, F, Pantaleo, G, Regenass, S, Rickenbach, M, Rudin, C, Schmid, P, Schultze, D, Schüpbach, J, Speck, R, de Tejada, BM, Taffé, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, and Yerly, S
- Abstract
Objectives: Antiretroviral therapy (ART) suppresses HIV viraemia, thereby reducing the antigenic drive for T cells to proliferate. Accordingly, selected HIV-specific T-cell responses have been described to contract within weeks of ART initiation. Here, we sought to investigate whether these findings apply to the entire repertoire of HIV-specific T cells. Methods: Using interferon (IFN)-γ enzyme linked immuno spot (ELISpot), we performed retrospective 2-year proteome-wide monitoring of HIV-specific T cells in 17 individuals with undetectable viral loads during ART. The sample pool for each study subject consisted of one pre-ART time-point and at least two time-points after initiation of therapy. Results: Peripheral pools of HIV-specific T cells decreased nonsignificantly within the first 2 years under ART in our cohort of patients, in terms of both breadth and magnitude. However, in most cases, the seeming decrease masked ongoing expansion of individual HIV-specific T-cell responses. We detected synchronous contraction and expansion of T-cell responses - with different peptide specificities - in 12 out of 17 study participants during follow-up. Importantly, the observed expansions and contractions of individual HIV-specific T-cell responses reached similar ranges, supporting the biological relevance of our findings. Conclusions: We conclude that successful ART enables both contraction and expansion of HIV-specific T-cell responses. Our results should prompt a renewed interest in HIV-specific T-cell dynamics under ART, in particular to elucidate the mechanisms that uncouple, to some extent, particular HIV-specific T-cell responses from variations in circulating antigen load and functionally characterize expanding/contracting T-cell populations beyond IFN-γ secretion. Assuming that expanding HIV-specific T-cell responses under ART are protective and functional, harnessing those mechanisms may provide novel opportunities for assisting viral control in chronically infected individuals. © 2012 British HIV Association.
- Published
- 2013
28. Routine peer benchmarking to lower antibiotic prescription in primary care – a pragmatic randomised trial to evaluate a complex intervention
- Author
-
Bucher, HC
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Background: Excessive use of antibiotics may raise bacterial resistance, an increasingly serious problem in Europe. In absolute terms most antibiotics (AB) are prescribed in primary care. Aim: To evaluate the effect of a continuous postal and web-based peer benchmark system of individual AB prescription[for full text, please go to the a.m. URL], Komplexe Interventionen – Entwicklung durch Austausch; 13. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin
- Published
- 2012
- Full Text
- View/download PDF
29. Risk of triple-class virological failure in children with HIV: a retrospective cohort study
- Author
-
Pursuing Later Treatment Options II project team for the Collaboration of Observational HIV Epidemiological Research Europe, Castro, H, Judd, A, Gibb, Dm, Butler, K, Lodwick, Rk, van Sighem, A, Ramos, Jt, Warsawski, J, Thorne, C, Noguera Julian, A, Obel, N, Costagliola, D, Tookey, Pa, Colin, C, Kjaer, J, Grarup, J, Chene, G, Collaborators: Antinori A, Phillips A., Castagna, A, Cozzi Lepri, A, De Luca, A, De Wit, S, Dorrucci, M, Duval, X, García, F, Ghosn, J, Günthard, H, Ledergerber, B, Lo Caputo, S, Lodwick, R, Masquelier, B, Meyer, L, Mocroft, A, Mussini, C, Paraskevis, D, Paredes, R, Pérez Hoyos, S, Phillips, A, Pillay, D, Podzamczer, D, Reiss, P, Stephan, C, Teira, R, Torti, Carlo, Touloumi, G, Zangerle, R, Warszawski, J, Dabis, F, Krause, Mm, Leport, C, de Wolf, F, Prins, M, Bücher, Hc, Sabin, C, Gibb, D, Fätkenheuer, G, Del Amo, J, Kirk, O, Antinori, A, Monforte, Ad, Tovo, Pa, de Martino, M, Brockmeyer, Nh, Battegay, M, Francioli, P, Carnicer Pont, D, Casabona, J, Miró, Jm, de Wit, S, Goetghebuer, T, Torti, C, Garrido, M, Dedes, N, Weller, I, d'Arminio Monforte, A, Collin Filleul, F, Schwimmer, C, Ellefson, M, Paulsen, M, Bohlius, J, Bouteloup, V, Bucher, Hc, Egger, M, Furrer, H, Lambotte, O, Lewden, C, Matheron, S, Miro, J, Puoti, M, Reekie, J, Smit, C, Sterne, J, Thiebaut, R, and Wittkop, L.
- Published
- 2011
30. Increasing Access to Hepatitis C Treatment in Rwanda: The Promise of RwandaâÂÂs Existing HIV Infrastructure
- Author
-
Kirk CM, Nsanzimana S, primary and Bucher HC, Uwizihiwe JP, additional
- Published
- 2015
- Full Text
- View/download PDF
31. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study
- Author
-
Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, Lodwick, Rk, Sabin, Ca, Porter, K, Ledergerber, B, van Sighem, A, Cozzi Lepri, A, Khaykin, P, Mocroft, A, Jacobson, L, De Wit, S, Obel, N, Castagna, A, Wasmuth, Jc, Gill, J, Klein, Mb, Gange, S, Riera, M, Mussini, C, Gutiérrez, F, Touloumi, G, Carrieri, P, Guest, Jl, Brockmeyer, Nh, Collaborators: Antoniadou A, Phillips A. N., Gargalianos Kakolyris, P, Katsarou, O, Kordossis, T, Lazanas, M, Panos, G, Paparizos, V, Paraskevis, D, Petrikkos, G, Sambatakou, H, Skoutelis, A, Pantazis, N, Bakoyannis, G, Gioukari, V, de Wolf, F, Bezemer, Do, Gras, La, Kesselring, Am, van Sighem AI, Smit, C, Zhang, S, Zaheri, S, Prins, Jm, Schreij, G, Bravenboer, B, van der Ende ME, Kauffmann, Rh, ten Kate RW, Kroon, Fp, Bronsveld, W, Vriesendorp, R, van Houte, D, ten Napel CH, Brinkman, K, van Eeden, A, Mulder, Jw, Juttmann, Jr, Veenstra, J, Koopmans, Pp, Sprenger, Hg, Hoepelman, Im, Danner, Sa, Richter, C, Tanis, Aa, Clumeck, N, Delforge, M, Necsoi, C, Demeester, R, Gennotte, Af, Gerard, M, Guillaume, Mp, Hermans, P, Kabeya, K, Konopnicki, D, Martin, C, Libois, A, Payen, Mc, Semaille, P, Van Laethem, Y, Del Amo, J, Meyer, L, Bucher, Hc, Chêne, G, Pillay, D, Prins, M, Rosinska, M, Sabin, C, Lodi, S, Coughlin, K, Walker, S, Babiker, A, Bucher, H, de Luca, A, Fisher, M, Muga, R, Fätkenheuer, G, Rockstroh, J, Vehreschild, J, Hertenstein, C, Berenguer, J, del Amo, J, García, F, Labarga, P, Moreno, S, Angeles Muñoz, M, Caro Murillo AM, Sobrino, P, Pérez Cachafeiro, S, Jarrín, I, Alejos, B, García, I, Gómez Sirvent, J, Soriano, V, Pulido, F, Iribarren, J, Masiá, M, Vidal, F, Sanz, J, Blanco, Ja, Sola, J, Gerstoft, J, Kronborg, G, Røge, B, Larsen, Cs, Pedersen, G, Laursen, Al, Nielsen, L, Jensen, J, Babacan, E, Bickel, M, Bodtländer, A, Brodt, Hr, Carlebach, A, Gute, P, Haberl, A, Helm, E, Klauke, S, Knecht, G, Lennemann, T, Locher, L, Lutz, T, Mösch, M, Müller, A, Nisius, G, Staszewski, S, Stephan, C, Stürmer, M, von Hentig, N, Wolf, T, Rimland, D, Moanna, A, Moorfield, M, Dorsey, M, Desilva, Ke, Schlueter Wirtz, S, Mindley, R, Dozier, R, Robinson, Y, Brown, P, Moroni, M, Angarano, G, Antinori, A, Carosi, G, Cauda, R, d'Arminio Monforte, A, Di Perri, G, Galli, M, Ghinelli, G, Iardino, R, Ippolito, G, Lazzarin, A, Mazzotta, F, Perno, Cf, Viale, Pl, Von Schlosser, F, Ammassari, A, Balotta, C, Bonfanti, P, Capobianchi, Mr, Ceccherini Silberstein, F, De Luca, A, Gervasoni, C, Girardi, E, Lo Caputo, S, Maggiolo, F, Murri, R, Puoti, M, Torti, Carlo, Salpietro, S, Marangione, M, Galli, L, Gianotti, N, Cossarini, F, Spagnuolo, V, Arendt, G, Esser, S, Jäger, H, Schwarze, S, Stoll, M, Wolf, H, Jansen, K, Michalik, C, Skaletz Rorowski, A, Königs, C, Gingelmaier, A, Margolick, Jb, Jacobson, Lp, Phair, Jp, Wolinsky, Sm, Detels, R, Rinaldo, Cr, Boirot, C, Bouhnik, Ad, Carrieri, Mp, Cassuto, Jp, Chesney, M, Cohen, J, Dellamonica, P, Dujardin, P, Gallais, H, Gastaut, Ja, Kurkdji, P, Lepeu, G, Mechali, D, Moatti, Jp, Moreau, J, Nègre, M, Obadia, Y, Poizot Martin, I, Pradier, C, Préau, M, Rey, D, Roux, P, Rouzioux, C, Sobel, A, Spire, B, Trémolières, F, Villes, V, Vincent, E, Vlahov, D, Borghi, V, Casabona, J, Miró, Jm, Gatell, Jm, López Dieguez Puerta, M, Tural, C, Clotet, B, Podzamczer, D, Ferrer, E, Murillas, J, Segura, F, Navarro, G, Force, L, Vilaró, J, Masabeu, A, Guadarrama, M, Betancourt, Aj, Romero, A, Agustí, C, Battegay, M, Bernasconi, E, Böni, J, Bürgisser, P, Calmy, A, Cavassini, M, Dubs, R, Egger, M, Elzi, L, Fischer, M, Flepp, M, Fontana, A, Francioli, P, Furrer, H, Fux, Ca, Gorgievski, M, Günthard, Hf, Hirsch, Hh, Hirschel, B, Hösli, I, Kahlert, C, Kaiser, L, Karrer, U, Kind, C, Klimkait, T, Martinetti, G, Martinez, B, Müller, N, Nadal, D, Paccaud, F, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schmid, P, Schultze, D, Schöni, F, Schüpbach, J, Speck, R, Taffé, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, Ainsworth, J, Anderson, J, Delpech, V, Dunn, D, Easterbrook, P, Gazzard, B, Gilson, R, Gompels, M, Hill, T, Johnson, M, Leen, C, Nelson, M, Orkin, C, Palfreeman, A, Phillips, A, Post, F, Schwenk, A, Walsh, J, Bansi, L, Huntington, S, Glabay, A, Anastos, K, Minkoff, H, Young, M, Greenblatt, R, Levine, A, Cohen, M, and Gange, S.
- Published
- 2010
32. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
- Author
-
Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe, Mocroft, A, Reiss, P, Kirk, O, Mussini, C, Girardi, E, Morlat, P, Stephan, C, De Wit, S, Doerholt, K, Ghosn, J, Bucher, Hc, Lundgren, Jd, Chene, G, Miro, Jm, Collaborators: Weller I, Furrer H., Costagliola, D, Ledergerber, B, Lundgren, J, Grarup, J, Touloumi, G, Warszawski, J, Meyer, L, Dabis, F, Krause, Mm, Leport, C, de Wolf, F, Porter, K, Dorrucci, M, Sabin, C, Gibb, D, Fätkenheuer, G, Del Amo, J, Obel, N, Thorne, C, Pérez Hoyos, S, Antinori, A, d'Arminio Monforte, A, Tovo, Pa, de Martino, M, Brockmeyer, Nh, Ramos, J, Battegay, M, Carnicer, D, Tookey, P, Casbona, J, Miró, Jm, Castagna, A, de Wit, S, Torti, Carlo, Teira, R, Garrido, M, Bucher, H, Egger, M, Furer, H, Lewden, C, Newell, Ml, Phillips, A, Stearne, J, Telenti, A, Collin Filleul, F, Ellefson, M, Fabre Colin, C, Kjaer, J, Schwimmer, C, Paulsen, M, and Dedes, N.
- Published
- 2010
33. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
- Author
-
Antiretroviral Therapy Cohort Collaboration, Mugavero, Mj, May, M, Harris, R, Saag, Ms, Costagliola, D, Egger, M, Phillips, A, Günthard, Hf, Dabis, F, Hogg, R, de Wolf, F, Fatkenheuer, G, Gill, Mj, Justice, A, D'Arminio Monforte, A, Lampe, F, Miró, Jm, Staszewski, S, Collaborators: Casabona J, Sterne J. A., Geneviè, C, del Amo, J, Fätkenheuer, G, Gill, J, Guest, J, Kitahata, M, Ledergerber, B, Mocroft, A, Reiss, P, Saag, M, Sterne, J, Sterne, Ja, Abgrall, S, Barin, F, Bentata, M, Billaud, E, Boué, F, Burty, C, Cabié, A, Cotte, L, De Truchis, P, Duval, X, Duvivier, C, Enel, P, Fredouille Heripret, L, Gasnault, J, Gaud, C, Gilquin, J, Grabar, S, Katlama, C, Khuong, Ma, Lang, Jm, Lascaux, As, Launay, O, Mahamat, A, Mary Krause, M, Matheron, S, Meynard, Jl, Pavie, J, Pialoux, G, Pilorgé, F, Poizot Martin, I, Pradier, C, Reynes, J, Rouveix, E, Simon, A, Tattevin, P, Tissot Dupon, H, Viard, Jp, Viget, N, Pariente Khayat, A, Salomon, V, Jacquemet, N, Rivet, A, Abgral, S, Guiguet, M, Kousignian, I, Lanoy, E, Lièvre, L, Potard, V, Selinger Leneman, H, Bouvet, E, Crickx, B, Ecobichon, Jl, Leport, C, Picard Dahan, C, Yeni, P, Tisne Dessus, D, Weiss, L, Salmon, D, Sicard, D, Auperin, I, Roudière, L, Fior, R, Delfraissy, Jf, Goujard, C, Jung, C, Lesprit, P, Desplanque, N, Meyohas, Mc, Picard, O, Cadranel, J, Mayaud, C, Bricaire, F, Herson, S, Clauvel, Jp, Decazes, Jm, Gerard, L, Molina, Jm, Diemer, M, Sellier, P, Berthé, H, Dupont, C, Chandemerle, C, Mortier, E, de Truchis, P, Honoré, P, Jeantils, V, Tassi, S, Mechali, D, Taverne, B, Gourdon, F, Laurichesse, H, Fresard, A, Lucht, F, Eglinger, P, Faller, Jp, Bazin, C, Verdon, R, Boibieux, A, Peyramond, D, Livroze, Jm, Touraine, Jl, Trepo, C, Ravaux, I, Tissot Dupont, H, Delmont, Jp, Moreau, J, Gastaut, Ja, Retornaz, F, Soubeyrand, J, Allegre, T, Blanc, Pa, Galinier, A, Ruiz, Jm, Lepeu, G, Granet Brunello, P, Esterni, Jp, Pelissier, L, Cohen Valensi, R, Nezri, M, Chadapaud, S, Laffeuillade, A, Laffeuillade, J, May, T, Rabaud, C, Raffi, F, Pugliese, P, Arvieux, C, Michelet, C, Borsa Lebas, F, Caron, F, Fraisse, P, Rey, D, Arlet Suau, E, Cuzin, L, Massip, P, Thiercelin Legrand MF, Yasdanpanah, Y, Pradinaud, R, Sobesky, M, Contant, M, Montroni, M, Scalise, G, Braschi, Mc, Riva, A, Tirelli, U, Cinelli, R, Pastore, G, Ladisa, N, Suter, F, Arici, C, Chiodo, F, Colangeli, V, Fiorini, C, Carosi, Giampiero, Cristini, G, Torti, Carlo, Minardi, C, Bertelli, D, Quirino, T, Manconi, Pe, Piano, P, Cosco, L, Scerbo, A, Vecchiet, J, D'Alessandro, M, Santoro, D, Pusterla, L, Carnevale, G, Zoncada, A, Viganò, P, Mena, M, Ghinelli, F, Sighinolfi, L, Leoncini, F, Mazzotta, F, Pozzi, M, Lo Caputo, S, Angarano, G, Grisorio, B, Saracino, A, Ferrara, S, Grima, P, Grima, F, Pagano, G, Cassola, G, Alessandrini, A, Piscopo, R, Toti, M, Trezzi, M, Soscia, F, Tacconi, L, Orani, A, Perini, P, Scasso, A, Vincenti, A, Chiodera, F, Castelli, P, Scalzini, A, Palvarini, L, Moroni, M, Lazzarin, A, Rizzardini, G, d'Arminio Monforte, A, Galli, A, Merli, S, Pastecchia, C, Moioli, Mc, Esposito, R, Mussini, C, Abresci, N, Chirianni, A, Izzo, Cm, Piazza, M, De Marco, M, Viglietti, R, Manzillo, E, Nappa, S, Colomba, A, Abbadessa, V, Prestileo, T, Mancuso, S, Ferrari, C, Pizzaferri, P, Filice, G, Minoli, L, Bruno, R, Novati, S, Baldelli, F, Tinca, M, Petrelli, E, Cioppi, A, Cioppi, F, Ruggieri, A, Menichetti, F, Martinelli, C, De Stefano, C, La Gala, A, Ballardini, G, Rizzo, E, Magnani, G, Ursitti, Ma, Arlotti, M, Ortolani, P, Cauda, R, Dianzani, F, Ippolito, G, Antinori, A, Antonucci, G, Ciardi, M, Narciso, P, Petrosillo, N, Vullo, V, De Luca, A, Zaccarelli, M, Acinapura, R, De Longis, P, Brandi, A, Trotta, Mp, Noto, P, Lichtne, M, Capobianch, Mr, Carletti, F, Girardi, E, Pezzotti, P, Rezza, G, Mura, Ms, Mannazzu, M, Caramello, P, Di Perri, G, Sciandra, M, Orofino, Gc, Grossi, Pa, Basilico, C, Poggio, A, Bottari, G, Raise, E, Ebo, F, Pellizzer, G, Buonfrate, D, Resta, F, Loso, K, Cozzi Lepri, A, Battegay, M, Bernasconi, E, Böni, J, Bucher, Hc, Bürgisser, P, Calmy, A, Cattacin, S, Cavassini, M, Dubs, R, Elzi, L, Fischer, M, Flepp, M, Fontana, A, Francioli, P, Furrer, H, Fux, C, Gorgievski, M, Günthard, H, Hirsch, H, Hirschel, B, Hösli, I, Kahlert, Ch, Kaiser, L, Karrer, U, Kind, C, Klimkait, T, Martinetti, G, Martinez, B, Martinez, N, Nadal, D, Opravil, M, Paccaud, F, Pantaleo, G, Rauch, A, Regenass, S, Rickenbach, M, Rudin, C, Schmid, P, Schultze, D, Schüpbach, J, Speck, R, Taffé, P, Telenti, A, Trkola, A, Vernazza, P, Weber, R, Yerly, S, Gras, La, van Sighem AI, Smit, C, Prins, Jm, Branger, J, Eeftinck Schattenkerk JK, Gisolf, J, Godfried, Mh, Lange, Jm, Lettinga, Kd, van der Meer JT, Nellen, Fj, van der Poll, T, Ruys, Ta, Steingrover, R, Vermeulen, Jn, Vrouenraets, Sm, van Vugt, M, Wit, Fw, Kuijpers, Tw, Pajkrt, D, Scherpbier, Hj, van Eeden, A, Brinkman, K, van den Berk GE, Blok, Wl, Frissen, Ph, Roos, Jc, Schouten, We, Mulder, Jw, van Gorp EC, Wagenaar, J, Veenstra, J, Danner, Sa, Van Agtmael MA, Claessen, Fa, Perenboom, Rm, Rijkeboer, A, van Vonderen MG, Richter, C, van der Berg, J, Vriesendorp, R, Jeurissen, Fj, Kauffmann, Rh, Pogány, K, Bravenboer, B, Sprenger, Hg, van Assen, S, van Leeuwen JT, Doedens, R, Scholvinck, Eh, ten Kate RW, Soetekouw, R, van Houte, D, Polée, Mb, Kroon, Fp, van den Broek PJ, van Dissel JT, Schippers, Ef, Schreij, G, van der Geest, S, Lowe, S, Verbon, A, Koopmans, Pp, Van Crevel, R, de Groot, R, Keuter, M, Post, F, van der Ven AJ, Warris, A, van der Ende ME, Gyssens, Ic, van der Feltz, M, Nouwen, Jl, Rijnders, Bj, de Vries TE, Driessen, G, van der Flier, M, Hartwig, Ng, Juttman, Jr, van Kasteren ME, Van de Heul, C, Hoepelman, Im, Schneider, Mm, Bonten, Mj, Borleffs, Jc, Ellerbroek, Pm, Jaspers, Ca, Mudrikove, T, Schurink, Ca, Gisolf, Eh, Geelen, Sp, Wolfs, Tf, Faber, T, Tanis, Aa, Groeneveld, Ph, den Hollander JG, Duits, Aj, Winkel, K, Back, Nk, Bakker, Me, Berkhout, B, Jurriaans, S, Zaaijer, Hl, Cuijpers, T, Rietra, Pj, Roozendaal, Kj, Pauw, W, van Zanten AP, Smits, Ph, von Blomberg BM, Savelkoul, P, Pettersson, A, Swanink, Cm, Franck, Pf, Lampe, As, Jansen, Cl, Hendriks, R, Benne, Ca, Veenendaal, D, Storm, H, Weel, J, van Zeijl JH, Kroes, Ac, Claas, Hc, Bruggeman, Ca, Goossens, Vj, Galama, Jm, Melchers, Wj, Poort, Ya, Doornum, Gj, Niesters, Mg, Osterhaus, Ad, Schutten, M, Buiting, Ag, Swaans, Ca, Boucher, Ca, Schuurman, R, Boel, E, Jansz, Af, Veldkamp, A, Beijnen, Jh, Huitema, Ad, Burger, Dm, Hugen, Pw, van Kan HJ, Losso, M, Duran, A, Vetter, N, Karpov, I, Vassilenko, A, Clumeck, N, De Wit, S, Poll, B, Colebunders, R, Machala, L, Rozsypal, H, Sedlacek, D, Nielsen, J, Lundgren, J, Benfield, T, Kirk, O, Gerstoft, J, Katzenstein, T, Hansen, Ab, Skinhøj, P, Pedersen, C, Zilmer, K, Girard, Pm, Saint Marc, T, Vanhems, P, Dietrich, M, Manegold, C, van Lunzen, J, Stellbrink, Hj, Staszewsk, S, Bickel, M, Goebel, Fd, Rockstroh, J, Schmidt, R, Kosmidis, J, Gargalianos, P, Sambatakou, H, Perdios, J, Panos, G, Filandras, A, Karabatsaki, E, Banhegyi, D, Mulcahy, F, Yust, I, Turner, D, Burke, M, Pollack, S, Hassoun, G, Sthoeger, Z, Maayan, S, Chiesi, A, Borghi, R, Pristera, R, Mazzott, F, Gabbuti, A, Vullo, Lichtner, M, Montesarchio, E, Iacomi, F, Finazzi, R, Viksna, L, Chaplinskas, S, Hemmer, R, Staub, T, Bruun, J, Maeland, A, Ormaasen, V, Knysz, B, Gasiorowski, J, Horban, A, Prokopowicz, D, Wiercinska Drapalo, A, Boron Kaczmarska, A, Pynka, M, Beniowski, M, Mularska, E, Trocha, H, Antunes, F, Valadas, E, Mansinho, K, Matez, F, Duiculescu, D, Babes, V, Streinu Cercel, A, Vinogradova, E, Rakhmanova, A, Jevtovic, D, Mokrás, M, Staneková, D, González Lahoz, J, Sánchez Conde, M, García Benayas, T, Martin Carbonero, L, Soriano, V, Clotet, B, Jou, A, Conejero, J, Tural, C, Gatell, Jm, Blaxhult, A, Karlsson, A, Pehrson, P, Soravia Dunand, V, Kravchenko, E, Chentsova, N, Barton, S, Johnson, Am, Mercey, D, Johnson, Ma, Murphy, M, Weber, J, Scullard, G, Fisher, M, Brettle, R, Loveday, C, Gatell, J, Johnson, A, Vella, S, Gjørup, I, Friis Moeller, N, Bannister, W, Mollerup, D, Podlevkareva, D, Holkmann Olsen, C, Kjaer, J, Raffanti, S, Dieterch, D, Becker, S, Scarsella, A, Fusco, G, Most, B, Balu, R, Rana, R, Beckerman, R, Ising, T, Fusco, J, Irek, R, Johnson, B, Hirani, A, Dejesus, E, Pierone, G, Lackey, P, Irek, C, Burdick, J, Leon, S, Arch, J, Helm, Eb, Carlebach, A, Müller, A, Haberl, A, Nisius, G, Lennemann, T, Stephan, C, Mösch, M, Gute, P, Locher, L, Lutz, T, Klauke, S, Knecht, G, Khaykin, P, Doerr, Hw, Stürmer, M, Babacan, E, von Hentig, N, Beylot, J, Chêne, G, Dupon, M, Longy Boursier, M, Pellegrin, Jl, Ragnaud, Jm, Salamon, R, Thiébaut, R, Lewden, C, Lawson Ayayi, S, Mercié, P, Moreau, Jf, Morlat, P, Bernard, N, Lacoste, D, Malvy, D, Neau, D, Blaizeau, Mj, Decoin, M, Delveaux, S, Hannapier, C, Labarrère, S, Lavignolle Aurillac, V, Uwamaliya Nziyumvira, B, Palmer, G, Touchard, D, Balestre, E, Alioum, A, Jacqmin Gadda, H, Bonarek, M, Bonnet, F, Coadou, B, Gellie, P, Nouts, C, Bocquentin, F, Dutronc, H, Lafarie, S, Aslan, A, Pistonne, T, Thibaut, P, Vatan, R, Chambon, D, De La Taille, C, Cazorla, C, Ocho, A, Viallard, Jf, Caubet, O, Cipriano, C, Lazaro, E, Couzigou, P, Castera, L, Fleury, H, Lafon, Me, Masquelier, B, Pellegrin, I, Breilh, D, Blanco, P, Loste, P, Caunègre, L, Bonna, F, Farbos, S, Ferrand, M, Ceccaldi, J, Tchamgoué, S, De Witte, S, Buy, E, Akagi, L, Brandson, E, Druyts, E, Gataric, Kf, Harrigan, Pr, Harris, M, Hayden, A, Lima, V, Montaner, J, Moore, D, Wood, E, Yip, B, Zhang, W, Bhagani, S, Byrne, P, Carroll, A, Cuthbertson, Z, Dunleavy, A, Geretti, Am, Heelan, B, Johnson, M, Kinloch de Loes, S, Lipman, M, Madge, S, Marshall, N, Nair, D, Nebbia, G, Prinz, B, Swaden, L, Tyrer, M, Youle, M, Chaloner, C, Grabowska, H, Holloway, J, Puradiredja, J, Ransom, D, Tsintas, R, Bansi, L, Fox, Z, Harris, E, Hill, T, Lodwick, R, Reekie, J, Sabin, C, Smith, C, Amoah, E, Booth, C, Clewley, G, Garcia Diaz, A, Gregory, B, Labbett, W, Tahami, F, Thomas, M, Read, R, Krentz, H, Beckthold, B, Faetkenheuer, G, Casabona, J, Miró, Jl, Alquézar, A, Esteve, A, Podzamczer, D, Murillas, J, Romero, A, Agustí, C, Agüero, F, Ferrer, E, Riera, M, Segura, F, Segura, G, Force, L, Vilaró, J, Masabeu, A, García, I, Guadarrama, M, Montoliu, A, Ortega, N, Lazzari, E, Puchol, E, Sanchez, M, Blanco, Jl, Garcia Alcaide, F, Martinez, E, Mallolas, J, López Dieguez, M, García Goez JF, Sirera, G, Romeu, J, Negredo, E, Miranda, C, Capitan, Mc, Olmo, M, Barragan, P, Saumoy, M, Bolaof, F, Cabellos, C, Peña, C, Sala, M, Cervantes, M, Amengual, Mj, Navarro, M, Penelo, E, Barrufet, P, Willig, Jh, Raper, Jl, Allison, Jj, Kempf, Mc, Schumacher, Je, Wes, Ao, Lin, Hy, Pisu, M, Moneyham, L, Vance, D, Bachmann, L, Davies, Sl, Berner, E, Acosta, E, King, J, Savage, K, Nevin, C, Walton, Fb, Marler, Ml, Lawrence, S, Files Kennedy, B, Batey, Ds, Patil, Ma, Patil, U, Varshney, M, Gibson, E, Guzman, A, Rinehart, D, Justice, Ac, Fiellin, Da, Bryant, K, Rimland, D, Jones Taylor, C, Oursler, Ka, Titanji, R, Brown, S, Garrison, S, Rodriguez Barradas, M, Masozera, N, Goetz, M, Leaf, D, Simberkoff, M, Blumenthal, D, Leung, J, Butt, A, Hoffman, E, Gibert, C, Peck, R, Mattocks, K, Braithwaite, S, Brandt, C, Cook, R, Conigliaro, J, Crothers, K, Chang, J, Crystal, S, Day, N, Erdos, J, Freiberg, M, Kozal, M, Gaziano, M, Gerschenson, M, Good, B, Gordon, A, Goulet, J, Kraemer, K, Lim, J, Maisto, S, Miller, P, O'Connor, P, Papas, R, Rinaldo, C, Roberts, M, Samet, J, Cohen, D, Consorte, A, Gordon, K, Kidwai, F, Levin, F, Mcginnis, K, Rambo, M, Rogers, J, Skanderson, M, and Whitsett, F.
- Published
- 2008
34. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study
- Author
-
Rauch, A, Rickenbach, M, Weber, R, Hirschel, B, Tarr, PE, Bucher, HC, Vernazza, P, Bernasconi, E, Zinkernagel, AS, Evison, J, Furrer, H, Swiss, HIV Cohort Study, University of Zurich, and Furrer, H
- Subjects
Microbiology (medical) ,Adult ,Male ,medicine.medical_specialty ,610 Medicine & health ,HIV Infections ,Rate ratio ,142-005 142-005 ,2726 Microbiology (medical) ,law.invention ,Men who have sex with men ,Cohort Studies ,Switzerland/epidemiology ,Condom ,Unsafe Sex ,Acquired immunodeficiency syndrome (AIDS) ,Unsafe Sex/ statistics & numerical data ,law ,Risk Factors ,Internal medicine ,medicine ,Prevalence ,Humans ,HIV Infections/ complications ,Seroconversion ,Homosexuality, Male ,Proportional Hazards Models ,ddc:616 ,Hepatitis C/ complications/ epidemiology ,business.industry ,Incidence (epidemiology) ,Incidence ,virus diseases ,2725 Infectious Diseases ,Hepatitis C ,medicine.disease ,Adult Cohort Studies Female HIV Infections/*complications Hepatitis C/*complications/*epidemiology *Homosexuality, Male Humans Incidence Male Prevalence Proportional Hazards Models Risk Factors Switzerland/epidemiology Unsafe Sex/*statistics & numerical data ,Infectious Diseases ,Immunology ,Female ,business ,Switzerland - Abstract
Background. Data on the incidence of hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)-infected persons are sparse. It is controversial whether and how frequently HCV is transmitted by unprotected sexual intercourse. Methods. We assessed the HCV seroprevalence and incidence of HCV infection in the Swiss HIV Cohort Study between 1988 and 2004. We investigated the association of HCV seroconversion with mode of HIV acquisition, sex, injection drug use (IDU), and constancy of condom use. Data on condom use or unsafe sexual behavior were prospectively collected between 2000 and 2004. Results. The overall seroprevalence of HCV infection was 33% among a total of 7899 eligible participants and 90% among persons reporting IDU. We observed 104 HCV seroconversions among 3327 participants during a total follow-up time of 16,305 person-years, corresponding to an incidence of 0.64 cases per 100 person-years. The incidence among participants with a history of IDU was 7.4 cases per 100 person-years, compared with 0.23 cases per 100 person-years in patients without such a history (P < .001). In men who had sex with men (MSM) without a history of IDU who reported unsafe sex, the incidence was 0.7 cases per 100 person-years, compared with 0.2 cases per 100 person-years in those not reporting unsafe sex (P = .02), corresponding to an incidence rate ratio of 3.5 (95% confidence interval, 1.2-10.0). The hazard of acquiring HCV infection was elevated among younger participants who were MSM. Conclusions. HCV infection incidence in the Swiss HIV Cohort Study was mainly associated with IDU. In HIV-infected MSM, HCV infection was associated with unsafe sex
- Published
- 2005
- Full Text
- View/download PDF
35. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials
- Author
-
Gloy, Vl, Briel, M, Bhatt, Dl, Kashyap, Sr, Schauer, Pr, Mingrone, Geltrude, Bucher, Hc, Nordmann, Aj, Mingrone, Geltrude (ORCID:0000-0003-2021-528X), Gloy, Vl, Briel, M, Bhatt, Dl, Kashyap, Sr, Schauer, Pr, Mingrone, Geltrude, Bucher, Hc, Nordmann, Aj, and Mingrone, Geltrude (ORCID:0000-0003-2021-528X)
- Abstract
To quantify the overall effects of bariatric surgery compared with non-surgical treatment for obesity.
- Published
- 2013
36. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.
- Author
-
Swiss HIV Cohort Study, Remy, B., Rickenbach, M., Schöni-Affolter, F., Vallet, Y., Francioli, MC., Barth, J., Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Burton-Jeangros, C., Calmy, A., Cavassini, M., Cellerai, C., Egger, M., Elzi, L., Fehr, J., Fellay, J., Flepp, M., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Rudin, C., Schmid, P., Schultze, D., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Telenti, A., Trkola, A., Vernazza, P., Weber, R., Yerly, S., Scherrer, A.U., von Wyl, V., Vernazza, P.L., Günthard, H.F., Swiss HIV Cohort Study, Remy, B., Rickenbach, M., Schöni-Affolter, F., Vallet, Y., Francioli, MC., Barth, J., Battegay, M., Bernasconi, E., Böni, J., Bucher, HC., Burton-Jeangros, C., Calmy, A., Cavassini, M., Cellerai, C., Egger, M., Elzi, L., Fehr, J., Fellay, J., Flepp, M., Francioli, P., Furrer, H., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hirschel, B., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Rudin, C., Schmid, P., Schultze, D., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Telenti, A., Trkola, A., Vernazza, P., Weber, R., Yerly, S., Scherrer, A.U., von Wyl, V., Vernazza, P.L., and Günthard, H.F.
- Abstract
BACKGROUND: Minor protease inhibitor (PI) mutations often exist as polymorphisms in HIV-1 sequences from treatment-naïve patients. Previous studies showed that their presence impairs the antiretroviral treatment (ART) response. Evaluating these findings in a larger cohort is essential. METHODS: To study the impact of minor PI mutations on time to viral suppression and time to virological failure, we included patients from the Swiss HIV Cohort Study infected with HIV-1 subtype B who started first-line ART with a PI and two nucleoside reverse transcriptase inhibitors. Cox regression models were performed to compare the outcomes among patients with 0 and ≥ 1 minor PI mutation. Models were adjusted for baseline HIV-1 RNA, CD4 cell count, sex, transmission category, age, ethnicity, year of ART start, the presence of nucleoside reverse transcriptase inhibitor mutations, and stratified for the administered PIs. RESULTS: We included 1199 patients of whom 944 (78.7%) received a boosted PI. Minor PI mutations associated with the administered PI were common: 41.7%, 16.1%, 4.7% and 1.9% had 1, 2, 3 or ≥ 4 mutations, respectively. The time to viral suppression was similar between patients with 0 (reference) and ≥ 1 minor PI mutation (multivariable hazard ratio (HR): 1.1 [95% confidence interval (CI): 1.0-1.3], P = .196). The time to virological failure was also similar (multivariable HR:.9 [95% CI:.5-1.6], P = .765). In addition, the impact of each single minor PI mutation was analyzed separately: none was significantly associated with the treatment outcome. CONCLUSIONS: The presence of minor PI mutations at baseline has no effect on the therapy outcome in HIV infected individuals.
- Published
- 2012
37. Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes.
- Author
-
Swiss HIV Cohort, Molecular Epidemiology of Tuberculosis Study Groups, Fenner, L., Egger, M., Gagneux, S., Tanner, M., Furrer, H., Böttger, EC., Frei, R., Bodmer, T., Ninet, B., Schrenzel, J., Jaton, K., Telenti, A., Siegrist, H., Pfyffer, GE., Bruderer, T., Dolina, M., Dubuis, O., Battegay, M., Bernasconi, E., Hoffmann, M., Cavassini, M., Hirschel, B., Calmy, A., Fehr, J., Janssens, JP., Stalder, JM., Helbling, P., Altpeter, E., Rieder, HL., Barth, J., Böni, J., Bucher, HC., Burton-Jeangros, C., Cellerai, C., Elzi, L., Fellay, J., Flepp, M., Francioli, P., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Trkola, A., Vernazza, P., Weber, R., Yerly, S., Janssens, J.P., Böttger, E.C., Swiss HIV Cohort, Molecular Epidemiology of Tuberculosis Study Groups, Fenner, L., Egger, M., Gagneux, S., Tanner, M., Furrer, H., Böttger, EC., Frei, R., Bodmer, T., Ninet, B., Schrenzel, J., Jaton, K., Telenti, A., Siegrist, H., Pfyffer, GE., Bruderer, T., Dolina, M., Dubuis, O., Battegay, M., Bernasconi, E., Hoffmann, M., Cavassini, M., Hirschel, B., Calmy, A., Fehr, J., Janssens, JP., Stalder, JM., Helbling, P., Altpeter, E., Rieder, HL., Barth, J., Böni, J., Bucher, HC., Burton-Jeangros, C., Cellerai, C., Elzi, L., Fellay, J., Flepp, M., Francioli, P., Fux, CA., Gorgievski, M., Günthard, H., Haerry, D., Hasse, B., Hirsch, HH., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Kind, C., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez de Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Trkola, A., Vernazza, P., Weber, R., Yerly, S., Janssens, J.P., and Böttger, E.C.
- Abstract
BACKGROUND: In Switzerland and other developed countries, the number of tuberculosis (TB) cases has been decreasing for decades, but HIV-infected patients and migrants remain risk groups. The aim of this study was to compare characteristics of TB in HIV-negative and HIV-infected patients diagnosed in Switzerland, and between coinfected patients enrolled and not enrolled in the national Swiss HIV Cohort Study (SHCS). METHODS AND FINDINGS: All patients diagnosed with culture-confirmed TB in the SHCS and a random sample of culture-confirmed cases reported to the national TB registry 2000-2008 were included. Outcomes were assessed in HIV-infected patients and considered successful in case of cure or treatment completion. Ninety-three SHCS patients and 288 patients selected randomly from 4221 registered patients were analyzed. The registry sample included 10 (3.5%) coinfected patients not enrolled in the SHCS: the estimated number of HIV-infected patients not enrolled in the SHCS but reported to the registry 2000-2008 was 146 (95% CI 122-173). Coinfected patients were more likely to be from sub-Saharan Africa (51.5% versus 15.8%, P<0.0001) and to present disseminated disease (23.9% vs. 3.4%, P<0.0001) than HIV-negative patients. Coinfected patients not enrolled in the SHCS were asylum seekers or migrant workers, with lower CD4 cell counts at TB diagnosis (median CD4 count 79 cells/µL compared to 149 cells/µL among SHCS patients, P = 0.07). There were 6 patients (60.0%) with successful outcomes compared to 82 (88.2%) patients in the SHCS (P = 0.023). CONCLUSIONS: The clinical presentation of coinfected patients differed from HIV-negative TB patients. The number of HIV-infected patients diagnosed with TB outside the SHCS is similar to the number diagnosed within the cohort but outcomes are poorer in patients not followed up in the national cohort. Special efforts are required to address the needs of this vulnerable population.
- Published
- 2012
38. Correlating HIV tropism with immunological response under combination antiretroviral therapy.
- Author
-
Bader, J, Schöni‐Affolter, F, Böni, J, Gorgievski‐Hrisoho, M, Martinetti, G, Battegay, M, Klimkait, T, Aubert, V., Bernasconi, E., Bucher, HC, Burton‐Jeangros, C, Calmy, A, Cavassini, M, Dollenmaier, G, Egger, M, Elzi, L, Fehr, J, Fellay, J, Furrer, H, and Fux, CA
- Subjects
CELL physiology ,CELL receptors ,CHEMOKINES ,HIV ,HIV infections ,IMMUNITY ,T cells ,VIRAL physiology ,ANTIRETROVIRAL agents ,HIGHLY active antiretroviral therapy ,DISEASE progression ,GENOTYPES - Abstract
Objectives A significant percentage of patients infected with HIV-1 experience only suboptimal CD4 cell recovery while treated with combination therapy ( cART). It is still unclear whether viral properties such as cell tropism play a major role in this incomplete immune response. This study therefore intended to follow the tropism evolution of the HIV-1 envelope during periods of suppressive cART. Methods Viruses from two distinct patient groups, one with good and another one with poor CD4 recovery after 5 years of suppressive cART, were genotypically analysed for viral tropism at baseline and at the end of the study period. Results Patients with CCR5-tropic CC-motif chemokine receptor 5 viruses at baseline tended to maintain this tropism to the study end. Patients who had a CXCR4-tropic CXC-motif chemokine receptor 4 virus at baseline were overrepresented in the poor CD4 recovery group. Overall, however, the majority of patients presented with CCR5-tropic viruses at follow-up. Conclusions Our data lend support to the hypothesis that tropism determination can be used as a parameter for disease progression even if analysed long before the establishment of a poorer immune response. Moreover, the lasting predominating CCR5-tropism during periods of full viral control suggests the involvement of cellular mechanisms that preferentially reduce CXCR4-tropic viruses during cART. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
39. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS)
- Author
-
Scherrer, AU, primary, Hasse, B, additional, Von Wyl, V, additional, Yerly, S, additional, Böni, J, additional, Bürgisser, P, additional, Klimkait, T, additional, Bucher, HC, additional, Ledergerber, B, additional, and Günthard, HF, additional
- Published
- 2009
- Full Text
- View/download PDF
40. PCV53 DRUG-ELUTING STENTS FROM A MEDICARE PAYER PERSPECTIVE: COST-UTILITY ANALYSIS WITH 4-YEAR CLINICAL META-ANALYSIS DATA
- Author
-
Bischof, M, primary, Briel, M, additional, Bucher, HC, additional, and Nordmann, A, additional
- Published
- 2008
- Full Text
- View/download PDF
41. Systemic procinetic pharmacologic treatment for postoperative adynamic ileus after abdominal surgery in adults
- Author
-
Traut, U, primary, Brügger, L, additional, Kunz, R, additional, Pauli-Magnus, C, additional, Haug, K, additional, Bucher, HC, additional, and Koller, MT, additional
- Published
- 2007
- Full Text
- View/download PDF
42. Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
- Author
-
Ciaffi, Laura, Cavassini, Matthias, Genne, Daniel, Delhumeau, Cecile, Spycher Elbes, Rachel, Hill, Andrew, Wandeler, Gilles, Fehr, Jan, Stoeckle, Marcel, Schmid, Patrick, Hirschel, Bernard, Montecucco, Fabrizio, Calmy, Alexandra, Aubert, V, Battegay, M, Bernasconi, E, Böni, J, Bucher, HC, Burton‐Jeangros, C, and Calmy, A
- Subjects
MEDICAL care of HIV-positive persons ,STATINS (Cardiovascular agents) ,DISEASE management ,CARDIOVASCULAR diseases ,HIGHLY active antiretroviral therapy ,HIV infections ,ETRAVIRINE (Drug) ,THERAPEUTICS - Abstract
Background Lifestyle changes and statins are the cornerstones in management of dyslipidaemia in patients with HIV infection. Replacement of an antiretroviral therapy ( ART) component is a proposed therapeutic strategy to reduce cardiovascular risk. In dyslipidaemic patients with HIV infection, we assessed the efficacy of replacing boosted protease inhibitor (b PI) or efavirenz ( EFV) by etravirine ( ETR) as an alternative to statin therapy. Materials and methods A prospective, open-label, multicentre, 12-week study of patients with HIV infection on ART including b PI or EFV, and statin treatment. Four weeks after statin interruption, b PI or EFV was switched to ETR (400 mg, 8 weeks) if serum low-density lipoprotein cholesterol ( LDL- C) was ≥ 3 mM. The primary endpoint was the proportion of patients on ETR with no indication for statin treatment at study completion. Serum levels of HIV RNA, lipids and biomarkers of cardiovascular disease were also measured. (ClinicalTrials.gov: NCT01543035). Results The 31 included patients had a HIV-1 RNA < 50 copies/mL (median age, 52 years; median CD4, 709 cell/mL; median LDL- C, 2·89 mM), 68% were on EFV, and 32% were on bPI. At week 4, 27 patients switched to ETR. At study completion, 15 patients (56%) on ETR did not qualify for statin treatment. After the ETR switch, serum levels of the cardiovascular biomarkers s ICAM and MCP1/ CCL2 decreased by 11·2% and 18·9%, respectively, and those of CCL5/ RANTES and tissue inhibitor of metalloproteinase-1 increased by 14·3% and 13·4%, respectively, indicating reduced cardiovascular risk. There were no notable treatment-related adverse events. Conclusions Replacing b PI or EFV by ETR is a viable strategy to obviate primary prevention statin treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
43. Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study.
- Author
-
Schäfer, J, Young, J, Bernasconi, E, Ledergerber, B, Nicca, D, Calmy, A, Cavassini, M, Furrer, H, Battegay, M, and Bucher, HC
- Subjects
DISEASE relapse ,HIV-positive persons ,LONGITUDINAL method ,MEDICAL cooperation ,SCIENTIFIC observation ,RESEARCH ,RESEARCH funding ,SMOKING cessation ,LOGISTIC regression analysis ,RECEIVER operating characteristic curves ,DESCRIPTIVE statistics ,PROGNOSIS - Abstract
Objectives The aim of the study was to assess whether prospective follow-up data within the Swiss HIV Cohort Study can be used to predict patients who stop smoking; or among smokers who stop, those who start smoking again. Methods We built prediction models first using clinical reasoning ('clinical models') and then by selecting from numerous candidate predictors using advanced statistical methods ('statistical models'). Our clinical models were based on literature that suggests that motivation drives smoking cessation, while dependence drives relapse in those attempting to stop. Our statistical models were based on automatic variable selection using additive logistic regression with component-wise gradient boosting. Results Of 4833 smokers, 26% stopped smoking, at least temporarily; because among those who stopped, 48% started smoking again. The predictive performance of our clinical and statistical models was modest. A basic clinical model for cessation, with patients classified into three motivational groups, was nearly as discriminatory as a constrained statistical model with just the most important predictors (the ratio of nonsmoking visits to total visits, alcohol or drug dependence, psychiatric comorbidities, recent hospitalization and age). A basic clinical model for relapse, based on the maximum number of cigarettes per day prior to stopping, was not as discriminatory as a constrained statistical model with just the ratio of nonsmoking visits to total visits. Conclusions Predicting smoking cessation and relapse is difficult, so that simple models are nearly as discriminatory as complex ones. Patients with a history of attempting to stop and those known to have stopped recently are the best candidates for an intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
44. PCV55 ECONOMIC EVALUATION OF DRUG ELUTING STENTS: COST-UTILITY ANALYSIS
- Author
-
Bischof, M, primary, Briel, M, additional, Bucher, HC, additional, and Nordmann, A, additional
- Published
- 2006
- Full Text
- View/download PDF
45. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials
- Author
-
Bucher, HC, Hengstler, P, and Schindler, C
- Subjects
Heart diseases -- Risk factors ,Risk factors (Health) -- Evaluation -- Physiological aspects ,Unsaturated fatty acids -- Physiological aspects -- Evaluation ,Health ,Evaluation ,Physiological aspects ,Risk factors - Abstract
Bucher HC, Hengstler P, Schindler C, Meier G. Am J Med 2002;112:298-304. PURPOSE: Observational studies have shown an inconsistent association between n-3 polyunsaturated fatty acids and the risk of coronary [...]
- Published
- 2002
46. Evidence-based Medicine: Wie beurteilte ich eine Studie zu einer therapeutischen Intervention?
- Author
-
Pewsner, D, primary, Jüni, P, additional, and Bucher, HC, additional
- Published
- 2001
- Full Text
- View/download PDF
47. Evidenced-based Medicine: comment juger une étude d'intervention?
- Author
-
Pewsner, D, primary, Jüni, P, additional, and Bucher, HC, additional
- Published
- 2001
- Full Text
- View/download PDF
48. Evidence-based Medicine: Wie beurteile ich eine Studie zu einem diagnostischen Test?
- Author
-
Glenck, U, primary, Pewsner, D, additional, and Bucher, HC, additional
- Published
- 2001
- Full Text
- View/download PDF
49. Evidence-based Medicine: comment juger une étude sur un test diagnostique?
- Author
-
Glenck, U, primary, Pewsner, D, additional, and Bucher, HC, additional
- Published
- 2001
- Full Text
- View/download PDF
50. Der Intuition auf der Spur? Das Bayes'sche Theorem und die Diagnostik in der Grundversorgung. Teil I
- Author
-
Pewsner, D, primary, Bleuer, JP, additional, Bucher, HC, additional, Battaglia, M, additional, Jüni, P, additional, and Egger, M, additional
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.